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CHAPTER 1: INTRODUCTION

1.1 Ductal Carcinoma In Situ (DCIS)
Breast cancer is one of the most common malignancies affecting United States
women, with up to 25% of these cases being in situ disease (Kuerer, Albarracin et al.
2009, Polyak 2010, Virnig, Tuttle et al. 2010, Brock, Ji et al. 2019). Breast ductal
carcinoma in situ (DCIS) is a pre-invasive condition in which abnormal cells proliferate
inside the mammary duct (Patani, Khaled et al. 2011). When these cells escape this
confined area by invading into the surrounding tissue the lesion is classified as invasive
breast ductal carcinoma (IDC), and patient prognosis becomes much less favorable
(Patani, Khaled et al. 2011, Boxer, Delaney et al. 2013).

1.1.1 The Use of Imaging in DCIS Management
With the advent of better detection systems [such as screening mammography
and in some cases magnetic resonance imaging (MRI)], more DCIS lesions are being
detected annually (Virnig, Tuttle et al. 2010, Van Cleef, Altintas et al. 2014). The primary
method for diagnosing DCIS is through the detection of micro-calcifications on
mammography followed by a biopsy of the lesion (Levinsohn, Altman et al. 2018).
However, in cases where extensive or high-grade disease is present MRI can instead
be used for evaluation. While MRI is more sensitive than mammography (~90% versus
~55%) it is much less specific (30-83%), can fail to identify low-grade lesions that lack
enough vascularization for detection, and is more expensive (Berg, Gutierrez et al.
2004, Bluemke, Gatsonis et al. 2004, Kuhl, Schrading et al. 2007). In a prospective
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analysis employing both MRI and mammography in the diagnosis of 352 DCIS patients,
screening mammography was found to be more accurate in estimating the size of
lesions (Pilewskie, Kennedy et al. 2013). This contradicts the findings from a previously
published retrospective report (Menell, Morris et al. 2005). While improvements in
imaging may partially account for this difference, the reported necessity of additional
biopsies after MRI by Pilewskie et al. argue that the benefits of using MRI over
mammography are uncertain. Until preoperative MRI screening can demonstrate
improved long-term outcomes, its application will likely continue on an individualized
basis. For women with dense breast tissue, ultrasound may also be used (Brem,
Lenihan et al. 2015). A more recent and potentially useful three-dimensional (3D)
imaging modality for DCIS is called tomosynthesis (also known as 3D mammography).
This imaging technique captures multiple images of each breast from different angles
and then reconstructs them as a set of three-dimensional images. While mainly
employed in the detection of invasive breast cancer, a population-based study found
that 1 in 16 DCIS lesions were only detected though this modality (Bernardi, Macaskill
et al. 2016). Though early detection is important, reports show that the current treatment
standard has room for improvement and a more nuanced understanding of DCIS
biology is required for effective disease intervention (Bleyer and Welch 2012, Gotzsche,
Jorgensen et al. 2012, Marmot, Altman et al. 2012, Kaur, Mao et al. 2013).

1.1.2 Treatment of DCIS
DCIS is a non-obligate precursor to IDC in which some lesions become invasive
and others remain indolent (Bijker, Donker et al. 2013, Cowell, Weigelt et al. 2013). In
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the past, DCIS was predominantly treated by mastectomy because it was believed to be
a multi-centric disease (Fonseca, Hartmann et al. 1997). However, with the
demonstration that the vast majority of DCIS are located at one site, breast
conservation surgery became a viable option (Holland, Schuurmans Stekhoven et al.
1990). To determine whether the administration of radiation therapy after breast
conservation surgery was reasonable for managing DCIS, the National Surgical
Adjuvant Breast and Bowel Project launched a randomized prospective clinical trial
(NSABP-B-17). 818 women with localized DCIS and negative margins were assigned to
either receive radiation or no additional therapy (Fisher, Land et al. 2001). The results
showed that with additional radiation, the rates of invasive occurrence (16.8% to 7.7%),
DCIS recurrence (14.6% to 8.0%), and overall tumor recurrence (31.7% to 15.7%) were
reduced by 50%. Now, many of these lesions are treated via breast conservation
surgery and radiotherapy (with or without hormone therapy) though bilateral
mastectomy can be implemented where genetically indicated (Kuerer, Albarracin et al.
2009, Bijker, Donker et al. 2013, Van Cleef, Altintas et al. 2014).

1.1.3 Oncotype DX Breast DCIS Score
An independent panel on breast cancer screening has concluded that early
detection reduces breast cancer mortality (Marmot, Altman et al. 2012). However, this
panel also acknowledges the occurrence of overtreatment. This means that in newly
diagnosed breast cancer cases, ~25% of which are DCIS, some could likely be
managed with less aggressive therapy—thereby reducing unnecessary patient risk and
financial burden. This dilemma has generated a need for reliable biomarkers or
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molecular determinants to assess invasive potential (Allred 2010, Hwang 2010,
Bombonati and Sgroi 2011, Patani, Khaled et al. 2011, Bijker, Donker et al. 2013,
Boxer, Delaney et al. 2013, Kaur, Mao et al. 2013).
At the present time there are no validated prognostic or predictive multigene
signatures that can successfully identify DCIS patients who are 1) at risk of invasive
recurrence, 2) whose risk is not further reduced by radiation therapy, and 3) whose
lesions warrant no adjuvant therapy (Hanna, Parra-Herran et al. 2019). However, there
is one clinically validated, commercially available multigene assay that can be used to
quantify the 10-year risk of local or invasive recurrence after a diagnosis of DCIS
without the addition of radiation therapy (Solin, Gray et al. 2013). This signature is a
subset of 12 genes—Ki-67, STK15, CNB1, MYBL2, PgR GSTM1, BIRC5, ACTB,
GAPDH, RPLPO, GUS, and TFRC—from the Oncotype DX Recurrence Score and is
aptly named the Oncotype DX Breast DCIS Score. There currently is a prospective nonrandomized clinical trial in Canada (DUCHESS; NCT02766881) whose objective is to
determine whether the Oncotype DX Breast DCIS Score is able to influence a doctor‘s
recommendation for radiotherapy as well as the treatment preference of patients with
low- or intermediate-risk DCIS (https://clinicaltrials.gov/ct2/show/NCT02766881). In the
US a similar study found that after receiving results from the assay surgeons changed
their treatment recommendations more often than radiation oncologists. Patients who
received their test results and completed their questionnaires also reported feeling less
anxious and feeling less conflict regarding what to do about their DCIS (Manders,
Kuerer et al. 2017). Unfortunately, the high cost associated with the DCIS score ($3416)
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has prevented its use in some areas (Raldow, Sher et al. 2016). This measure is not
currently standard of care (Alvarado, Lucci et al. 2017).

1.1.4 Prospective Studies on Active Surveillance
Five clinical trials (LORD, LORIS, COMET, LARRIKIN, and LORETTA) have
been initiated to determine whether or not active surveillance is a viable treatment
option for patients with low-risk DCIS (Elshof, Tryfonidis et al. 2015, Francis, Thomas et
al. 2015, Lippey, Spillane et al. 2016, Groen, Elshof et al. 2017, Kanbayashi and Iwata
2017, Hwang, Hyslop et al. 2019). The Low-risk DCIS study (LORD; NCT02492607) is
a multicenter, randomized phase III non-inferiority trial. Non-inferiority trials are
designed to demonstrate that an experimental treatment is not substantially worse than
a control treatment. LORD‘s objective is to determine whether low-risk DCIS detected
through screening can be safely managed by active surveillance or if local strategies
(here, wide local excision alone, wide local excision plus radiotherapy, or mastectomy,
with or without the additions of hormone therapy) should remain the standard of care.
1240 women will be assigned to either the surveillance or treatment arm of the trial. The
primary outcome measure for LORD is ipsilateral invasive breast cancer-free rate at 10
years post-randomization (Elshof, Tryfonidis et al. 2015). Many of the same parameters
apply for the Low Risk DCIS Trial (LORIS; ISRCTN: 27544579). Key differences include
the acceptance of patients who present with grade I or II DCIS (as opposed to grade I
only), and an enrollment target of 932 (Francis, Thomas et al. 2015). The Comparison
of Operative to Monitoring and Endocrine Therapy Trial for Low Risk DCIS (COMET;
NCT02926911) and Low and Intermediate Risk Ductal Carcinoma In Situ (LARRIKIN)
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trials predominantly differ from LORD and LORIS in that they both allow participants
under active surveillance to choose additional hormone therapy. COMET‘s primary
endpoint is to assess the rate of invasive cancer in the affected breast at two and five
years and seeks to enroll 1200 US women with grade I or II DCIS, irrespective of
necrosis/comedonecrosis (Hwang, Hyslop et al. 2019). LARRIKIN‘s primary endpoint is
to assess ipsilateral breast cancer free survival at five and 10 years and seeks to enroll
470 women from Australia or New Zealand with grade I or II DCIS. Monitoring for all
four trials will be carried out using some form of screening mammography (Lippey,
Spillane et al. 2016, Groen, Elshof et al. 2017). The last clinical study is known as
Single-arm Confirmatory Trial of Endocrine Therapy Alone for Estrogen Receptorpositive, Low-risk Ductal Carcinoma In Situ of the Breast (LORETTA; JCOG1505).
LORETTA mandates hormone therapy, and is open to Japanese women with
ER+/HER2- DCIS that are grade I or II and exhibit no comedo necrosis. The primary
endpoint for this trial is five-year cumulative incidence of invasive ipsilateral breast
tumors which will be monitored using mammography, ultrasound, as well as MRI, and
enrollment is capped at 340 participants (Kanbayashi and Iwata 2017). The results for
each of these trials are eagerly awaited.
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1.2 In Vitro Models for Studying Invasive Transitions of DCIS
Last year roughly one out of every four newly diagnosed cases of breast
carcinoma was ductal carcinoma in situ (DCIS) (Siegel, Miller et al. 2018). Many women
diagnosed with DCIS will receive unnecessary care because we currently lack
biomarkers to help differentiate between indolent pre-invasive lesions and those which
may progress to invasive ductal carcinoma (IDC) (Bleyer and Welch 2012, Narod, Iqbal
et al. 2015, Hanna, Parra-Herran et al. 2019). There is an unmet need to identify
biologically important markers in DCIS (Lari and Kuerer 2011). In order to help define
these markers and allow for more rational, individualized treatment, models that
accurately recapitulate disease are needed (Cowell, Weigelt et al. 2013). We and others
are developing such systems in order to identify and validate pathways that play key
roles in the transition of DCIS to IDC. The systems include mouse models, conventional
two-dimensional (2D) monolayer cultures on plastic, and 3D cultures in natural or
synthetic matrices. Some culture models are comprised solely of DCIS cells (either cell
lines or primary cells). Others are co-cultures, in which additional cell types found in the
normal or cancerous human breast are added. 3D co-culture models can be particularly
informative because they have been shown to accurately mimic the structural and
functional changes in the architecture of the cancerous breast as shown elegantly by
Bissell and colleagues (for review, see (Schmeichel and Bissell 2003, Weigelt and
Bissell 2008, Weigelt, Ghajar et al. 2014)). Each model system has its own merits and
can be a useful tool for answering specific questions. The advantages and
disadvantages of in vivo modeling have been discussed in an elegant review (Behbod,
Gomes et al. 2018). The following sections will focus on in vitro systems, their ability to
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recapitulate disease biology, and how they may serve as a reproducible and
quantifiable preclinical screen for testing therapeutic strategies.

1.2.1 DCIS Cell Lines
Our understanding of cell culture has changed dramatically over the years. As a
community, we now know that tumor cells do not ―dedifferentiate‖ immediately upon
being placed in culture; rather that early methods gave certain stromal components
(e.g., fibroblasts) the edge they needed to take over the sample (Sato 2008). Similarly,
our understanding of how to apply this technique to biomedical research has also
evolved.
The maintenance of cells isolated from a single source on plastic, also known as
2D culture, acts as the data workhorse of many research labs around the world. This is
especially true in the broad field of cancer research (Sharma, Haber et al. 2010), where
a plethora of cell lines are available and provide a relatively cheap, renewable source of
biological material for the characterization of various tumor types. Generally speaking,
when cultured in the absence of other cell types (mono-culture), these cell lines express
the hallmarks of cancer (Hanahan and Weinberg 2011) with the exceptions of
angiogenesis and evading immune destruction, which require endothelial and immune
cells, respectively. This makes them ideal for identifying important oncogenes and
tumor suppressors, discerning the mechanism of action for drugs, as well as
understanding cell signaling and how pathways may contribute to pathogenesis in a
particular context. Of course, the relevance of any cell line is dependent on how closely
it resembles the state that it is supposed to model, and with so many cell lines available
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some are inevitably less beneficial than others. Furthermore, the patient-to-patient
heterogeneity of these diseases means that no single-source model will ever accurately
represent all cases. Therefore, validating research findings using models comprised of
cells from more than one line or patient will continue to be an important practice. This
and other factors [reviewed in more detail here (van Staveren, Solis et al. 2009, Gillet,
Varma et al. 2013)] have made the usefulness of cell lines a well-debated topic for
many decades. Encouragingly, these matters have not only put a greater emphasis on
careful study design and the proper handling of chosen lines, they have also led to the
creation of more applicable model systems.
There are many human breast cancer cell lines available that can be employed
to better understand various aspects of this malignancy. However, despite the fact that
DCIS comprises such a high proportion of newly diagnosed cases of breast cancer, the
same cannot be said for DCIS cell lines. This is likely due to the relatively small size of
DCIS lesions as compared to established, invasive breast tumors. With less tissue, it is
difficult to establish cell lines. As a result, the handful of established DCIS cell lines that
do exist (MCF10DCIS.com in the MCF10 series, S3 in the HMT-3522 series, 21NT in
the 21T series, h.DCIS.01, SUM102PT, and SUM225) have proved to be invaluable to
the field, and represent a variety of breast cancer subtypes. Even so, established cell
lines that are cultured over long periods of time can undergo changes in their molecular
profiles. A potential solution is the generation of new cell lines from patient-derived
xenograft models or tumor cells in which fewer alterations from the original tumor have
occurred.
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HER2-negative DCIS cell lines: MCF10DCIS.com (also referred to as
MCF10.DCIS) is an ER-negative/PR-negative/HER2-negative basal-like cell line that
recapitulates DCIS structures when grown in mice (Miller, Santner et al. 2000, Behbod,
Kittrell et al. 2009, Jedeszko, Victor et al. 2009) and under 3D culture conditions (Li,
Mullins et al. 2008, Jedeszko, Victor et al. 2009). As the naming convention suggests,
this line is part of the MCF10 series of breast cancer progression which also includes
non-transformed breast epithelial cells (MCF10A), premalignant variants (MCF10AT),
as well as malignant variants (MCF10CA). These isogenic lines originated from tissue
provided by a 36 year-old woman with fibrocystic breast disease who underwent a
reduction mammoplasty (Soule, Maloney et al. 1990). MCF10A cells immortalized
spontaneously and do not form xenografts in nude mice. However, the isogenic cell
lines derived from MCF10A (MCF10DCIS.com and the variants of MCF10AT and
MCF10CA), were stably transfected with T24 H-Ras oncogene and do grow as
xenografts (Basolo, Elliott et al. 1991). The MCF10DCIS.com line, cloned from an
MCF10AT xenograft after it had undergone two successive trocar passages, forms
predominantly high-grade comedo DCIS in vivo (Miller, Santner et al. 2000). At three
weeks these lesions are not invasive, however, some have been observed to progress
to IDC after nine weeks. Why some of the DCIS lesions progress to IDC is not known; it
is however intriguing that this model recapitulates the heterogeneity observed in
patients. Of potential relevance is that Natrajan and colleagues have reported that the
MCF10 series harbors relevant driver alterations that are also seen in primary breast
cancers (e.g., PIK3CA) (Maguire, Peck et al. 2016). Despite the infrequency of HRAS
mutation in primary breast lesions, the authors conclude that these cell lines represent a
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good model for studying disease progression and evaluating potential biomarkers or
therapeutic targets. This is further supported by the dependence for some variants in
the series on epidermal growth factor supplementation (e.g., MCF10DCIS.com,
MCF10CA) despite their expression of an oncogenic H-Ras. On the other hand,
functional activation of wild-type Ras in breast cancers through overexpressed growth
factors and their receptors (Eckert, Repasky et al. 2004) is thought to be a more
common occurrence, and thus therapeutics that target Ras may be useful in disease
treatment (Li and Sparano 2003).
Another ER-negative/PR-negative/HER2-negative DCIS line is S3 of the HMT3522 human breast epithelial cell line series (S1, S2, S3, T4-2) (Rizki, Weaver et al.
2008). The HMT-3522 cell lines like the MCF10 cell lines are derived from a patient with
fibrocystic breast

disease

who

underwent

reduction mammoplasty.

S1

cells

immortalized spontaneously and S2 cells were established through continuous cell
passaging in defined medium. The S2 cells gave rise to both the pre-invasive S3 and
invasive T4-2 cells through 3D culture in laminin-rich basement membrane or
implantation in nude mice, respectively. In Boyden chamber assays, S1, S2, and S3 cell
lines do not invade whereas T4-2 cells do. However, when S3 cells are exposed to
conditioned medium from T4-2 cells they become invasive, with the S3-C variant having
the highest invasive potential. Importantly, orthotopic transplantation of the series into
the mammary fat pad results in increases in tumor frequency from S1 (no tumors) to T42 (many tumors) that parallel the rates of invasion in Boyden chamber assays. The HMT
series is well-established (Wang, Weaver et al. 1998) and models metaplastic disease,
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with the S3 line operating similarly to MCF10DCIS.com as a DCIS that is poised to
invade (Rizki, Weaver et al. 2008).
SUM102PT is also an ER-negative/PR-negative/HER2-negative DCIS cell line
(https://sumlineknowledgebase.com/?page_id=1181). The origin of this cell line differs
from the two examples above as it was derived from a 56 year-old woman who had
undergone neo-adjuvant chemotherapy followed by modified radical mastectomy for a
minimally invasive apocrine adenocarcinoma with extensive DCIS (Sartor, Dziubinski et
al. 1997). This line is dependent on epidermal growth factor receptor (EGFR) signaling
for growth, and overexpresses the receptor without gene amplification. SUM102PT is
classified as a basal-like model of DCIS with micro-invasion (Forozan, Veldman et al.
1999) and has been studied in both 3D culture (Jedeszko, Victor et al. 2009, Kaur, Mao
et al. 2012) and nude mice (Eck, Côté et al. 2009).
Another example of an ER-negative/PR-negative/HER2-negative cell line is
h.DCIS.01. This line was derived from a primary culture of hyperplastic breast epithelial
cells (columnar cell hyperplasia) and form lesions in vivo that are similar to those
formed by MCF10DCIS.com. At later passages (>30) these cells spontaneously
transformed in culture into a cell line exhibiting a DCIS-like phenotype (Lee, Stewart et
al. 2012).
HER2-positive DCIS cell lines: HER2-positive DCIS lesions have a significantly
higher risk for local in situ recurrence (Curigliano, Disalvatore et al. 2015). HER2positivity is also associated with invasive breast cancers of higher stages than is HER2negativity (Mustafa, DeStefano et al. 2017). Therefore, cell lines that are HER2-positive
are needed to model DCIS. To date, there are only two cell lines that fit this description:
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SUM225 and 21NT from the 21T series, both of which exhibit HER2 amplification.
SUM225 was isolated through culturing a chest wall recurrence from a patient with
DCIS treated by mastectomy (Forozan, Veldman et al. 1999). Notably, SUM225 forms
dysplastic structures in both 3D culture models (Kaur, Mao et al. 2012) and in vivo in an
intraductal mouse model (Behbod, Kittrell et al. 2009). The 21T series is comprised of
four cell lines: 21PT, 21NT, 21MT-1, and 21MT-2. These were obtained from a 36 yearold woman who was first diagnosed with infiltrating and intraductal carcinoma, then
developed lung metastases a year later (Band, Zajchowski et al. 1990). 21PT and 21NT
were collected from separate primary lesions and serve as models of atypical ductal
hyperplasia and DCIS, respectively. 21MT-1 and 21MT-2 were both isolated from a
metastatic pleural effusion after mastectomy and chemotherapy, with the former more
closely resembling the primary tumor and the latter displaying a much more aggressive
profile (Band, Zajchowski et al. 1990). In 3D, 21PT cells, in contrast to 21NT cells,
formed acinar structures with lumens (Souter, Andrews et al. 2010). The most striking
difference between the 21PT and 21NT cells though is their ability to form tumors in
nude mice (21NT cells can form tumors, but 21PT cannot). 21NT xenografts mimic
comedo DCIS with neoplastic cells filling the entire mammary fat pad duct. This model
of HER-positive DCIS, as well as the SUM225 cell line, represent a valuable research
tools.
ER-positive/PR-positive cell lines: There are few ER-positive/PR-positive models
of DCIS. Lee and colleagues reported the creation of five ER-positive/PR-positive DCIS
cell lines in 2014 (Yong, Choong et al. 2014). All five cell lines derive from a single
source, i.e., a pre-invasive DCIS excised from a 47 year-old Chinese woman. These
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cells were transfected with a pGRN145 vector containing hTERT and antibiotic
resistance sequences. Single cell colonies were then allowed to grow under selection
for at least two weeks, leading to the generation of ETCC006, ETCC007, ETCC008,
ETCC010, and ETCC011 lines. Of these, ETCC006 (and to a lesser degree ETCC010)
resembled the original lesion the closest with regard to expression of pan-cytokeratin,
cytokeratin-19, vimentin, estrogen receptor α/β, and progesterone receptor. HER2
expression was indirectly assessed through treatment with trastuzumab/Herceptin and
no response was reported. The parental line and ETCC008 were non-tumorigenic over
a 90-day period as assessed by subcutaneous transplantation into severe combined
immunodeficiency female mice. In contrast, ETCC006, ETCC007, ETCC010 and
ETCC011 all showed tumor growth after 50 days. To date these lines have not been
studied by other laboratories.

1.2.2 2D DCIS Mono-cultures as Tools for Understanding Pathology
Some progress has been made in understanding how DCIS relates to invasive
breast cancer using 2D mono-cultures. Porter and colleagues used MCF10DCIS.com
2D mono-cultures, xenografts, and patient tissue to elucidate the role of singleminded2s (SIM2s) in malignant progression (Scribner, Behbod et al. 2013). Their previous work
had suggested that SIM2s is a tumor suppressor and that, by inhibiting epithelial to
mesenchymal transition signaling and promoting differentiation, SIM2s maintains the
integrity of the epithelium (Kwak, Gustafson et al. 2007, Laffin, Wellberg et al. 2008,
Gustafson, Wellberg et al. 2009, Wellberg, Metz et al. 2010, Scribner, Wellberg et al.
2011). In their 2013 paper, Porter and colleagues analyzed the effect of modulating
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SIM2s expression on DCIS progression (Scribner, Behbod et al. 2013). SIM2s
expression in patient tissues decreases from normal to DCIS to IDC, and with
malignancy in breast cell lines. Scribner et al. found that stable knockdown of SIM2s in
MCF10DCIS.com cells results in an increase in proliferation and invasiveness. In
contrast, overexpression of SIM2s inhibits proliferation, yet has no effect on
invasiveness. Changes in expression of several matrix metalloproteinases (MMPs) are
observed in subcutaneous xenografts generated from the cells in which SIM2s
expression had been manipulated (i.e., MMP1, MMP2, MMP3, MMP10). MMP
expression was analyzed in the xenografts, but not in the cells in mono-culture.
Therefore, it is not possible to assess whether the changes in expression of MMPs
reflect changes induced in host cells that have infiltrated into the xenografts, changes in
the MCF10DCIS.com cells or a combination of the two. Porter and colleagues
concluded that SIM2s may play a role in breast cancer progression, and that expression
of the protein can promote tumor differentiation (Scribner, Behbod et al. 2013).
MCF10DCIS.com 2D mono-cultures have also been used to assess possible
treatment strategies that will induce DCIS differentiation, such as activation of
peroxisome proliferator-activated receptor gamma (PPARγ) (Ory, Kietzman et al. 2018).
PPARγ signaling is known to affect multiple cellular processes, including differentiation,
proliferation, and apoptosis in both normal and cancerous tissue (Michalik, Desvergne
et al. 2004). Ory et al. tested effects of a third-generation PPARγ agonist, efatutazone
(Ory, Kietzman et al. 2018). In 2D mono-cultures, they observed increased expression
of luminal epithelial markers and decreased expression of basal epithelial markers,
suggesting the cells had differentiated. They also analyzed effects on 3D cultures of
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MCF10DCIS.com cells grown in reconstituted basement membrane (rBM) and on
xenografts. Tumorsphere formation by 3D rBM cultures was reduced as was
invasiveness of the xenografts, both consistent with efatutazone treatment inducing
differentiation. Thus, by using 2D mono-cultures of DCIS cells, two pathways that can
induce differentiation and delay progression of DCIS have been identified. In both
cases, the results have been validated in xenograft models. The complex changes in
MMPs in the study on SIM2s and the changes in expression of inflammatory response
pathway genes in the study on PPARγ suggest a need to consider possible effects on
the microenvironment as well as on DCIS cells.

1.2.2 3D DCIS Mono-cultures as Tools for Understanding Pathology
Culturing tumor cells in 2D, even with the addition of other relevant cell types,
only provides a small part of the biological picture because many of the checks and
balances are missing. In 3D culture, tumor cells grow in an architecture which allows for
cell:cell and cell:ECM interactions similar to those found in vivo. This advantage makes
3D culture modeling particularly relevant in the preclinical setting for predicting drug
efficacy and toxicity [for review, see (Katt, Placone et al. 2016, Lv, Hu et al. 2017,
Maddaly, Subramaniyan et al. 2017, Ravi, Ramesh et al. 2017)]. Using DCIS cell lines
and cells isolated from patient samples, 3D studies have been performed by Bundred
and colleagues (Farnie, Clarke et al. 2007, Farnie, Willan et al. 2013, Farnie, Johnson
et al. 2014, Williams, Bundred et al. 2015). The DCIS cells were grown in non-adherent
3D cultures as mammospheres because this technique is known to select for cells that
exhibit stem-like properties and express E-cadherin on their surface (Manuel Iglesias,
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Beloqui et al. 2013). In this assay the only matrix produced comes from the DCIS cells.
Notably, mammosphere formation is reduced by inhibiting EGFR or Notch signaling with
gefitinib or Notch 4-neutralizing antibody, respectively (Farnie, Clarke et al. 2007).
Furthermore inhibiting Notch indirectly in combination with EGFR or Her2/neu was
shown to be more effective than monotherapy (Farnie, Willan et al. 2013).
Mammosphere formation by DCIS cells was also reduced by targeting a novel focal
adhesion kinase-Wnt/beta-catenin signaling pathway that regulates DCIS stem cell
activity (Williams, Bundred et al. 2015). These mammosphere studies support the use
of 3D DCIS mono-cultures as preclinical models for drug discovery.
While mammosphere studies could be interpreted as evidence that the
interactions of DCIS cells—which produce basement membrane containing collagen
IV—with the surrounding matrices—where collagen I is deposited by fibroblasts—are of
little importance for drug discovery, there are matrix-related risk factors for breast
cancer development. Among these are increases in mammographic density due to
elevated collagen I deposition (Alowami, Troup et al. 2003); increases in local tissue
stiffness due to changes in the mechanical properties of collagen I [for review, see
(Butcher, Alliston et al. 2009)]; and changes in matrix topography due to realignment of
collagen I fibers (Riching, Cox et al. 2014). Importantly, changes in collagen I have been
observed preclinically in mice as well as in patient DCIS lesions. In an example of the
former, a mouse model of postpartum breast cancer revealed increases in fibrillar
collagen for DCIS lesions (Lyons, O'Brien et al. 2011). Prior to this, a study involving
human DCIS lesions showed that two proteins which increase extracellular matrix
stiffness (the collagen cross-linker lysyl oxidase and the lysyl oxidase-like protein) were
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found to colocalize at sites of stromal reactions (Decitre, Gleyzal et al. 1998). In
addition, DCIS lesions show increased expression of focal adhesion kinase, a
downstream pathway in stimulation of collagen I production (Cance, Harris et al. 2000,
Wong, Rustad et al. 2011, Zhao, Cheng et al. 2016). The effect of extracellular matrix
stiffness on MCF10DCIS.com cells grown in 3D cultures (rBM overlay cultures plated on
collagen I-coated glass slides calibrated to different pascals of stress) have also been
evaluated (Wei, Fattet et al. 2015). Increased pascal counts induced nuclear
translocation of the transcription factor TWIST1 in these DCIS cells, a response
conserved in breast epithelial cells. When the cytoplasmic partner of TWIST1, the Ras
GTPase-activating protein-binding protein 2 (G3BP2) was reduced in MCF10DCIS.com
cells, the TWIST1-G3BP2 mechanotransduction pathway was activated, inducing
epithelial to mesenchymal transition and invasiveness. These results, however, are
inconsistent with those of Gupta et al. who reported that high expression of G3BP2,
which regulates initiation of breast cancer, is associated with poor survival of breast
cancer patients (Gupta, Badeaux et al. 2017). Perhaps the differential expression of
G3BP2 between DCIS and invasive disease represents a useful marker of progression.
Two hypotheses on the acquisition of invasiveness that characterizes the DCIS
to IDC transition have been the focus of many DCIS progression studies. One proposes
that molecular and genetic alterations occur in the DCIS cells and lead to this change
while the other posits that the cross-talk between DCIS cells and their microenvironment
(i.e., matrices, stromal cells and pathochemical factors) is ultimately important. Profiling
of DCIS patient samples has revealed 1) significant changes in gene expression in
association with the transition to IDC (Hu, Yao et al. 2008, Burkhardt, Grob et al. 2010,

19

Muggerud, Hallett et al. 2010, Knudsen, Ertel et al. 2012, Lee, Stewart et al. 2012), 2)
similarities in gene expression and mutation in epithelial cells from in situ and invasive
regions (Ma, Salunga et al. 2003, Schuetz, Bonin et al. 2006, Vincent-Salomon,
Lucchesi et al. 2008, Petridis, Brook et al. 2016), and 3) both changes and similarities
(Ma, Salunga et al. 2003, Hernandez, Wilkerson et al. 2012). These disparate results
may be partially due to difficulties in obtaining DCIS lesions from patients that do not
contain contaminating cells even when using laser capture microdissection techniques
(Perou, Sorlie et al. 2000, Luzzi, Holtschlag et al. 2001). One solution for gathering the
necessary supportive data is isolating RNA from a pure population, such as cultured
DCIS cells (Kaur, Mao et al. 2012, Kaur, Mao et al. 2013). SPRY4, encoding for Sprouty
Homolog 4, is one example of a gene candidate found using this approach.
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1.3 Sprouty
Sprouty is a developmental protein in Drosophila that regulates branching during
organogenesis (Hacohen, Kramer et al. 1998, Leeksma, Van Achterberg et al. 2002).
Like many genes discovered in fruit flies, SPRY was named based on its mutationassociated phenotype. In this case, Drosophila expressing mutated SPRY showed
excessive branching or ―sprouting‖ at the stalks of primary tracheal branches (Hacohen,
Kramer et al. 1998). Subsequent work performed by Freeman and colleagues
determined that Sprouty was an intracellular protein tightly associated with the plasma
membrane (Casci, Vinos et al. 1999). This change is thought to be important for its role
in signal modulation and allows the protein to affect cellular processes such as
proliferation, differentiation, motility, and survival (Masoumi-Moghaddam, Amini et al.
2014). Casci et al. also showed strong interactions between Sprouty and Drk (Grb2
homologue) as well as Gap1 (Ras-Gap) using pull-downs. Surprisingly, neither of these
interactions required the cysteine-rich domain in Sprouty‘s C-terminal region which the
authors showed to be important for plasma membrane targeting. While its activity was
originally described as a genetic inhibitor of FGF signaling and then as an antagonist of
both the EGFR and FGF pathways, we now know that Sprouty primarily acts to
suppress growth factor-induced extracellular signal-regulated kinase/mitogen-activated
protein kinase (ERK/MAPK) signaling (Hacohen, Kramer et al. 1998, Kramer, Okabe et
al. 1999, Reich, Sapir et al. 1999).

1.3.1 Mammalian Homologs of Sprouty
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There are four mammalian homologs of Sprouty, designated Sproutys 1-4 (de
Maximy, Nakatake et al. 1999). Like their Drosophila counterpart, these homologs are
thought to negatively regulate ERK/MAPK signaling stimulated by receptor tyrosine
kinase (RTK) activity (Lo, Yusoff et al. 2004, Cabrita and Christofori 2008, MasoumiMoghaddam, Amini et al. 2014). They also share three structural motifs or domains that
are believed to contribute to their function or regulation (see Figure 1.1). These include
a c-Cbl tyrosine kinase-binding binding motif, a serine-rich motif, and a cysteine-rich
domain (also known as the sprouty domain or the translocation domain) (Guy, Jackson
et al. 2009). The c-Cbl tyrosine kinase-binding binding motif (NXYpTXXP) is centered on
a key, phosphorylatable tyrosine residue and enables the sprouty protein to bind this
E3-ubiquitin ligase. Once bound, subsequent ubiquitination and degradation occurs,
though to differing extents depending on how conserved this sequence is for each
sprouty family member (Ng, Jackson et al. 2008). For example, Sprouty4, unlike
Sprouty2, lacks the conserved threonine which is thought to enhance binding affinity,
and phosphorylation of the conserved tyrosine is not required for Sprouty4‘s regulatory
function (Masoumi-Moghaddam, Amini et al. 2014). Unsurprisingly, Sprouty2 is more
effectively regulated by c-Cbl than Sprouty4. Mutation of the key tyrosine residue has
also been shown to produce a dominant-negative effect for mouse Sprouty2 and
Sprouty4 (Y55A and Y53A, respectively) (Sasaki, Taketomi et al. 2001).
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Figure 1.1 Structural similarities between Sprouty homologs. Sprouty proteins share a number of
structurally important motifs and domains, shown above in blue, green, and purple. The blue represents a
c-Cbl tyrosine kinase-binding motif centered on a key, phosphorylatable tyrosine residue that allows the
protein to bind the E3-ubiquitin ligase. The green represents a serine-rich motif which is hypothesized to
be part of or control a critical hinge region on the sprouty proteins; Dephosphorylation within the motif
appears to be the ‗on‘ switch while phosphorylation is the ‗off‘ switch. Purple boxes represent the
cysteine-rich domain (also known as the sprouty domain or the translocation domain). This region
contains 24 cysteine residues, 19 of which are conserved across all four homologs. The cysteine-rich
domain has been shown to mediate homo- and hetero-dimerization between homologs, membrane
localization, as well as protein-protein interaction.
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While the serine-rich motif is conserved across all four homologs, it only appears
to be relevant to the function of Sprouty2. While both Sprouty1 and Sprouty2 undergo
serine phosphorylation, this motif appears to control an important hinge region in
Sprouty2‘s tertiary structure where phosphorylation status acts as a switch
(Impagnatiello, Weitzer et al. 2001, Lao, Yusoff et al. 2007). In contrast the cysteine-rich
domain is a region containing 24 cysteine residues, 19 of which are conserved across
all four homologs (Guy, Jackson et al. 2009). This region has been shown to mediate
homo- and hetero-dimerization between family members, membrane localization, as
well as protein-protein interactions (Lim, Wong et al. 2000, Ozaki, Miyazaki et al. 2005,
Tsumura, Toshima et al. 2005, Masoumi-Moghaddam, Amini et al. 2014). Despite these
conserved sequences sprouty proteins do not appear to share a major mode of action
and lack any recognizable protein interaction domain. This may be partially accounted
for by the variability present in their N-termini, as sprouty homologs are known to
function differently in various tissue types (Masoumi-Moghaddam, Amini et al. 2014).
However, it also makes the question ―how and where do they function?‖ difficult to
answer, with most proposals coming out of screens for interacting partners [reviewed in
(Guy, Jackson et al. 2009, Masoumi-Moghaddam, Amini et al. 2014)].

1.3.2 Sprouty4 in Normal Physiology
In 2002 Leeksma et al. identified the human SPRY4 gene and mapped its
location to chromosomal position 5q31.3. Human SPRY4 has two verified, proteincoding transcript variants which measure 2.4 and 4.9 kilo-base pairs (kb), respectively.
Multiple tissue Northern blotting revealed that the 4.9-kb transcript was the primary
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mRNA expressed in vivo. In vitro transcription-translation of this 4.9-kb transcript
identified an open reading frame of 322 amino acids, generating a protein with an
approximate molecular mass of 35 kDa (Leeksma, Van Achterberg et al. 2002).
Important features contained within this amino acid sequence include three potential
SH3-binding proline-rich regions (suggesting the ability to modulate signal transduction),
a MAPK consensus sequence phosphorylation site, as well as a PEST domain which is
normally associated with proteins that have a short intracellular half-life (Gonzalez,
Raden et al. 1991, Rechsteiner and Rogers 1996, Sattler and Salgia 1998, Leeksma,
Van Achterberg et al. 2002). Additionally, the conserved tyrosine in human Spry4 is
located at position 75 in the N-terminal sequence, 23 further down than its mammalian
counterpart (position 52) (Leeksma, Van Achterberg et al. 2002).
In order to assess function, Leeksma et al. performed acute stimulation
experiments using epidermal growth factor or insulin, as well as Ras activity assays in
A14 cells (NIH 3T3 cells stably expressing a human insulin receptor under a SV40
promoter). Under these conditions, Sprouty4 was able to suppress ERK/MAPK and Ras
activity. However, constitutive MAPK signaling achieved through the use of a V12
mutant Ras was unaffected by hSpry4 expression, arguing that Sprouty4 exerts its
regulatory function upstream of Ras or possibly at the level of wild-type Ras (Leeksma,
Van Achterberg et al. 2002). In contrast, more recent studies have shown that Sprouty4
binds to Raf proteins (Sasaki, Taketomi et al. 2003, Tsavachidou, Coleman et al. 2004).
While the exact location of this regulation is still contested, most of the field agrees that
Sprouty4 is able to suppress ERK activity (Leeksma, Van Achterberg et al. 2002,
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Sasaki, Taketomi et al. 2003, Tsavachidou, Coleman et al. 2004, MasoumiMoghaddam, Amini et al. 2014).
Sprouty4 has been studied extensively during development. In both zebrafish
and mice, proper SPRY4 expression is required to form a normal cerebellum
(Fürthauer, Reifers et al. 2001, Yu, Yaguchi et al. 2011). Sprouty4 is downregulated in
mice during postnatal brain development where it regulates axon growth (Hausott,
Vallant et al. 2012). In mouse and chick embryos Sprouty4 appears to act as an
inhibitor of FGF signaling, (e.g., during chick limb bud development). Due to this
behavior, SPRY4 as well as other SPRY genes may play a role in the pathogenesis of
human chondrodysplasias if overexpressed (de Maximy, Nakatake et al. 1999,
Minowada, Jarvis et al. 1999). Furthermore, inducing SPRY4 expression during murine
lung development interfered with branching morphogenesis, lobulation, and proper
formation of the peripheral parenchyma (Perl, Hokuto et al. 2003). Mouse embryos
overexpressing SPRY4 in their endothelium exhibit disorganized and primitive vascular
networks in the head, heart, and intersomatic vessels indicating that Sprouty4 inhibits
vascular branching during angiogenesis (Lee, Schloss et al. 2001). Finally, disparate
results were observed in two independent SPRY4 knockout mouse models. In one
model the authors showed that Sprouty2 and Sprouty4 cooperatively work to control
tooth development (Klein, Minowada et al. 2006). In the other, reduced viability due to
mandible defects were reported (survivors exhibited polysyndactyly and slower growth
rates). SPRY2/SPRY4 double knockout mice were embryonic lethal (Taniguchi, Ayada
et al. 2007). Taken together, these studies of Sprouty4—and others performed with the
other homologs—strongly implicate sprouty proteins in the regulation of branching
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tissues (e.g., lung, kidney, blood vessels, prostate, breast ducts) during development
(Guy, Wong et al. 2003).

1.3.3 Sprouty4 in Breast Cancer
Sprouty4 has been studied in a wide variety of cancers, including breast, ovarian,
endometrial, colorectal, gastrointestinal stromal tumors, glioma, liver, lung, pancreatic,
prostate, testicular germ cell tumors, melanoma, select sarcomas, esophageal
squamous cell carcinoma, and acute myeloid leukemia (Lo, Fong et al. 2006, Wang,
Thompson et al. 2006, Jaggi, Cabrita et al. 2008, Gromova, Ralea et al. 2009,
Taniguchi, Ishizaki et al. 2009, Tennis, Van Scoyk et al. 2010, Faratian, Sims et al.
2011, Mirabello, Kratz et al. 2012, Sirivatanauksorn, Sirivatanauksorn et al. 2012,
Rathmanner, Haigl et al. 2013, Li, Zhang et al. 2014, Vanas, Muhlbacher et al. 2014, Li,
Huynh et al. 2015, Masoumi-Moghaddam, Amini et al. 2015, Ramsdale, Jorissen et al.
2015, Shaverdashvili, Zhang et al. 2015, Sun, Huang et al. 2015, Zhao, Chen et al.
2015, Doriguzzi, Salhi et al. 2016, He, Jing et al. 2016, Jing, Liaw et al. 2016, Kitai, Ebi
et al. 2016, Zhang, Guo et al. 2016, Zhou, Xie et al. 2016, Chai, Fan et al. 2017,
Kayser, Feszler et al. 2017, Zhang, Han et al. 2017, Das, Furu et al. 2018, Tian, Fu et
al. 2018, Kumar, Njauw et al. 2019, Zhang, Wang et al. 2019). However, seeing as this
study is about in situ breast carcinoma, this section will focus on Sprouty4‘s
documented role in breast cancer.
In 2011 Faratian et al. conducted a meta-analysis of six gene expression
datasets comprising 1,107 primary human breast cancers. SPRY4 transcript was
significantly higher in basal-like and normal-like tumors, though no significant
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differences were seen with increasing grade, HER2 status, or in comparison to normal
breast tissue (Faratian, Sims et al. 2011). Subsequent work from another group utilizing
reverse transcription‑polymerase chain reaction and immunoblotting on a panel of
breast cancer cell lines suggested that Sprouty4 expression is likely not regulated at the
transcript level in cancer but instead at the protein level (Doriguzzi, Salhi et al. 2016).
This finding has since been challenged by the discovery that miR-181 (which targets the
3‘ untranslated region of SPRY4) may function as an onco-miR in breast cancer (Tian,
Fu et al. 2018). The effects of ectopic Sprouty4 expression have been tested in vitro.
MCF-7 breast cancer cells overexpressing Sprouty4 exhibited reduced proliferation and
ERK/MAPK levels compared to controls. In addition, MDA-MB-231 cells showed
reduced proliferation and migration upon Sprouty4 overexpression (Vanas, Muhlbacher
et al. 2014). Knockdown of Sprouty4 in MDA-MB-231 cells was subsequently shown to
increase proliferation, migration, and anchorage-independent growth in vitro, as well as
tumor growth and metastasis in vivo (Jing, Liaw et al. 2016).

1.3.4 Next Generation Sequencing and Sprouty4
We previously performed microarray and next-generation/deep sequencing
(NGS) analyses on RNA isolated from 3D rBM mono-cultures of three DCIS cell lines
(MCF10DCIS.com, SUM102PT, and SUM225) and the MCF10A non-transformed
human breast epithelial cell line. Of the 157 differentially expressed genes identified by
microarray (see Figure 1.2), 63 were found to be up-regulated between the DCIS and
non-transformed models using NGS. Our DCIS transcriptome signature (Kaur, Mao et
al. 2012) (NCBI: GSE 36863) was validated by the identification of genes previously
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associated with DCIS, i.e., transforming growth factor beta 1 (TGFB1) (Calaf, EchiburuChau et al. 2008), dystonin (DST) (Lee, Stewart et al. 2012), high-temperature
requirement a serine peptidase 1 (HTRA1) (Wang, Eckert et al. 2012), and gap junction
protein beta 2 (GJB2) (Castellana, Escuin et al. 2012). Using the Genomatix Pathway
System we identified two highly-enriched common frameworks (336-fold and 254-fold)
in the promoters of 3 and 4 genes, respectively, in the human genome.

29

Figure 1.2 Microarray reveals differential gene expression between three models of DCIS and
MCF10A. The results of transcriptomic analysis comparing the 3D culture expression of three DCIS
models: MCF10.DCIS, SUM102 and SUM225 to a non-transformed breast epithelial model: MCF10A.
157 of the genes were differentially expressed in the three DCIS lines compared to MCF10A.
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Pursuing these potential target genes has led to some intriguing findings for
those able to influence the invasive capability of malignant breast cancer cells. An
example of this from the 254-fold enriched framework is the gene encoding for C-C
motif chemokine ligand 20 (CCL20), also known as macrophage inflammatory protein-3
alpha. Secretion of CCL20 increases in 3D rBM mono-cultures of MCF10 variants from
atypical hyperplastic to DCIS and remains high in the isogenic IDC cell line.
Furthermore, when highly malignant MDA-MB-231 cells are grown under the same
conditions but in the presence of a neutralizing antibody to human CCL20, we observed
a reduction in both invasion and proteolysis (Brock, Ji et al. 2019).
Genes that appear to play a role in DCIS progression were also found by our
study in the 336-fold enriched framework (see Table 1). One of these, RAP1GAP has
now been shown to be a potential switch for progression toward an invasive phenotype
(Shah, Brock et al. 2018). The confirmation of this hit led to further investigation of an
equally strong candidate, SPRY4, which encodes the protein Sprouty4. Given that
oncogenes often become active earlier in cancer development, it seems reasonable that
more delayed molecular changes, such as the loss of growth suppressors, would drive
premalignant lesions toward invasion (Wang, Hoque et al. 2003). Validating the
functional roles of targets such as these found in our screen may identify biomarkers for
discriminating indolent lesions from premalignant lesions and also may reveal new
therapeutic targets.
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Table 1 Genomatix Pathway System analysis reveals a potential mechanism for coordinate upregulation of three candidate genes in DCIS. Bioinformatic data mining performed on up-regulated
genes identified via transcriptomic analyses. 244 promoters were associated with 63 up-regulated genes
and substantial enrichment was observed in the common promoter framework between three candidates,
one of which was SPRY4.
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1.4 E-cadherin
The proper formation of tissues during development requires cellular polarization,
aggregation, segregation, and migration to all coordinate, and each of these processes
requires the expression of specific adhesion proteins (Wheelock and Johnson 2003). In
1984 the Takeichi laboratory proposed the term ―cadherin‖ to describe a calciumdependent cell-cell adhesion system that had been observed in a number of cell types
and embryonic tissues (Yoshida-Noro, Suzuki et al. 1984). Since then 100+ cadherin
proteins have been described, and a large body of work has accumulated on epithelial
or E-cadherin. This single-pass transmembrane protein is frequently found in adherens
junctions which are structures located near the apical surface of polarized epithelial
cells (Wheelock and Johnson 2003). E-cadherin interacts with β-catenin from the
cytoplasmic side of the junction and, in turn, β-catenin interacts with the N-terminal
domain of α-catenin (Hulsken, Birchmeier et al. 1994, Jou, Stewart et al. 1995). ΑCatenin then interacts with the actin cytoskeleton either directly or indirectly via actin
binding proteins (e.g., α-actinin, vinculin), linking E-cadherin to the cytoskeleton
(Knudsen, Soler et al. 1995, Rimm, Koslov et al. 1995, Weiss, Kroemker et al. 1998).
Most human cancers originate from epithelial tissues. Not surprisingly, a large
proportion of cancer-related cadherin studies focus on E-cadherin (Wheelock and
Johnson 2003). IHC analyses show that E-cadherin is frequently lost in many tumors,
including breast, and it is believed that this reduction is important for invasion (Hajra and
Fearon 2002). Downregulation of E-cadherin can occur through several mechanisms,
including gene mutations (which often coincide with loss of heterozygosity), promoter
methylation, transcriptional repression, and posttranslational modification of the
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cadherin/catenin complex (Berx, Becker et al. 1998, Hajra and Fearon 2002, Wheelock
and Johnson 2003). Important to this project, it has been shown that Snail and Slug are
able to repress E-cadherin mRNA and protein expression in breast cancer cell lines,
and that Slug—but not Snail—expression was correlated with this event in vivo (Hajra,
Chen et al. 2002).
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1.5 The Role of Cytoskeletal Remodeling in Invasion
The three major components of the cytoskeleton are microfilaments, intermediate
filaments, and microtubules. Microfilaments are created when the polymerized form of
actin, known as filamentous or F-actin, complexes with actin-binding proteins (Fife,
McCarroll et al. 2014). This actin cytoskeleton participates in a number of important
cellular processes including motility, division, polarization, and cytokinesis (Doherty and
McMahon 2008). In the presence of external growth factors or chemokines cells can
mobilize by becoming polarized and extending membranous protrusions made of Factin toward the extracellular cue (Pollard and Borisy 2003). These actin protrusions are
temporarily stabilized by connections linking the cytoskeleton to the ECM that, upon
movement, disassemble at the rear of the cell to allow the trailing cell body to retract
(Ridley, Schwartz et al. 2003).
While the process of cellular migration is necessary in normal biological function
(e.g., immune surveillance), deviant activation of migratory signaling in cancer cells
promotes disease progression by enabling invasion and metastasis (Yamaguchi and
Condeelis 2007). During these processes, the actin cytoskeleton reorganizes to
promote a more motile, mesenchymal-like cellular phenotype (Thiery, Acloque et al.
2009). This contrasts with normal epithelial cells where actin forms cortical ring-like
structures which are associated with cell-cell adhesions (Haynes, Srivastava et al.
2011).

35

1.6 The RTK/RAS/ERK Signaling Pathway
Mitogen-activated protein kinases (MAPKs) are responsible for converting
extracellular stimuli into an array of cellular responses. There are four conventional
MAPK transduction cascades in mammals: the p38, JNK1/2/3, ERK5, and the ERK1/2
cascade alluded to earlier in this work (Pritchard and Hayward 2013). Each of these
cascades is comprised of three evolutionarily conserved kinases: a MAPKK kinase
(MAPKKK), and a MAPK kinase (MAPKK) and a MAPK. When triggered, MAPKKK
proteins phosphorylate serine residues on MAPKKs which, in turn, phosphorylate a
conserved threonine/tyrosine motif (Thr-X-Tyr) on MAPKs (Cargnello and Roux 2011).
This transduction occurs rapidly and is used as a way to amplify the signal, convert
graded inputs into on/off outputs, and to filter out low level noise (Santen, Song et al.
2002). In the context of the ERK1/2 cascade (see Figure 1.3), growth factors bind to
RTKs that autophosphorylate and recruit adaptor proteins (e.g., Grb2). Guanine
nucleotide exchange factors such as Son of Sevenless then bind and facilitate the
activation of a small GTPase (i.e., Ras) by allowing GTP to replace GDP. GTP-Ras
signaling then leads to the activation of the MAPKKK (i.e., Raf), MAPKK (i.e., MEK1/2),
and eventually the MAPK (i.e., ERK1/2) which then translocates to the nucleus to
regulate gene expression (Santen, Song et al. 2002, Sundaram 2013, Najafi, Ahmadi et
al. 2019). Canonically, the RTK-Ras-ERK1/2 pathway is a signaling cascade that
governs cellular proliferation, differentiation, migration, senescence, and apoptosis
(Sundaram 2013, Sun, Liu et al. 2015, Najafi, Ahmadi et al. 2019). In breast cancer, this
pathway has been shown to be overactive under both hormone-dependent and
independent conditions [reviewed in (Santen, Song et al. 2002)]. Indeed, it can be
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argued that the ERK1/2 pathway is the most relevant MAPK cascade for breast cancer,
especially in the case of triple-negative disease active MEK and ERK profiles are found
to be up-regulated (Santen, Song et al. 2002, Hoeflich, O'Brien et al. 2009, Mirzoeva,
Das et al. 2009).
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Figure 1.3 The canonical RTK-Ras-ERK signaling cascade. Growth factors bind to receptor tyrosine
kinases that autophosphorylate and recruit adaptor proteins (e.g., Grb2). Guanine nucleotide exchange
factors such as Sos then bind and facilitate the activation of Ras by allowing GTP to replace GDP. Ras
signaling then leads to the activation of Raf, MEKs 1/2, and eventually ERKs 1/2 which translocate to the
nucleus to regulate gene expression.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Materials
Trypsin/EDTA solution and penicillin-streptomycin (pen/strep) were obtained from
Cellgro (Herndon, VA). Horse serum was purchased from HyClone Laboratories
(Logan, UT). Quenched fluorescein-conjugated collagen type IV (DQ-collagen IV) was
obtained from Molecular Probes (Eugene, OR). The MEK inhibitor PD184352 was
supplied by Pfizer (New York, NY). The MEK inhibitor U0126 and its inactive analog
U0124 were purchased from Calbiochem (San Diego, CA). The MEK inhibitor MEK162
was supplied by Novartis Pharma (Basel, Switzerland). 5x siRNA buffer was obtained
from GE Dharmacon (Lafayette, CO). Insulin, hydrocortisone, epidermal growth factor,
lipofectamine 2000, opti-MEM reduced serum medium, phosphate-buffered saline
(PBS), puromycin, hoechst 33342, 4′,6-diamidino-2-phenylindole (DAPI), vectashield
antifade mounting medium, and Alexa Fluor 555 donkey anti-mouse fluorescent
secondary antibody (A-31570) were purchased from Thermo Fisher Scientific (Waltham,
MA). Enhanced chemiluminescence detection agents and autoradiography film were
purchased from Denville Scientific (Holliston, MA). Horseradish peroxidase-conjugated
donkey anti-mouse and donkey anti-rabbit IgG antibodies were purchased from Jackson
ImmunoResearch Laboratories Inc. (West Grove, PA). Rabbit anti-Sprouty4 (ab115557)
antibody was purchased from Abcam (Cambridge, MA). Rabbit anti-Sprouty1 (D9V6P;
#13013), rabbit anti-Sprouty2 (D3G1A; #14954), rabbit anti-Slug (C19G7; #9585), rabbit
anti-phospho-MEK1/2 Ser217/221 (41G9; #9154), rabbit anti-total MEK1/2 (D1A5;
#8727), rabbit anti-phospho ERK1/2 (D13.14.4E; #4370), and rabbit anti-total MAPK
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(#9102) antibodies were from Cell Signaling (Danvers, MA). Mouse anti-phospho-MAPK
(MAPK-YT; #M8159) antibody, fluorescein isothiocyanate labeled phalloidin (P5282),
and phorbol 12-myristate 13-acetate, phenylmethylsulfonyl fluoride, leupeptin, and
aprotinin were obtained from Sigma-Aldrich (St. Louis, MO). Mouse anti-E-cadherin
(#610181) antibody was purchased from BD Biosciences (San Jose, CA). Mouse betatubulin (clone E7) antibody was obtained from the Developmental Studies Hybridoma
Bank (Iowa City, IA). Reduced growth factor reconstituted basement membrane
(Cultrex; #3445-005-01) was purchased from Trevigen (Gaithersburg, MD).

40

2.2 Cell Culture: 2D and 3D
The MCF10 human breast epithelial progression series of cells (MCF10A,
MCF10.AT1, MCF10.DCIS, and MCF10.CA1d) were obtained from the Biobanking and
Correlative Sciences Core at the Karmanos Center Institute, Detroit, MI. Cell lines were
authenticated using the STR PowerPlex 16 System (Promega) and confirmed to be free
of mycoplasma by microscopy (MycoFluor; Thermo Fisher Scientific) and PCR (Venor
GeM; Sigma-Aldrich). All cell lines were maintained as monolayer cultures at 37°C with
5% CO2. 2D culture was performed using DMEM/F-12, HEPES, no phenol red medium
(Fisher Scientific; 11039047) supplemented with 5% horse serum, 1% pen/strep, 10
µg/mL insulin, 0.5 µg/mL hydrocortisone, and 20 ng/mL epidermal growth factor. For 3D
culture where the endpoint was immunoblotting, dishes were coated with 16 mg/mL
Cultrex. After solidification of the matrix, a single-cell suspension in 3D assay medium
(DMEM/F-12, HEPES, no phenol red medium supplemented with 2% horse serum, 2%
Cultrex, 1% pen/strep, 960 ng/mL insulin, 50 ng/mL hydrocortisone, and 0.5 ng/mL
epidermal growth factor) was pipetted on top of the matrix and grown for eight days,
with assay media being changed after four days. For 3D immunocytochemistry, assay
media were not changed during the eight day period.
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2.3 Viral Infection for Stable Overexpression & shRNA Knockdown of Sprouty4
Plasmids from bacteria transformed with each of the two pLPCX/Spry4
constructs (generous gifts from M. Tennis) were extracted and purified using Biorad‘s
Quantum Prep Plasmid Miniprep Kit (Hercules, CA). The contents of each construct
were verified using Sanger sequencing services provided by Wayne State University.
Overexpression of Sprouty4 in the MCF10.CA1d cell line was achieved using HEK293T
cells to package 3 µg of plasmid inside retrovirus as previously described (Li, Mullins et
al. 2008). MCF10.CA1d cells were transduced for six hours then allowed to recover
before starting negative selection with 5 µg/mL puromycin. Two independent isolates of
Sprouty4 with 6x His tags following the C-terminal residues were generated in this
background and labeled MCF10.CA1d/S1 and MCF10.CA1d/S2. The MCF10.CA1d/S2
cells exhibited a stronger overexpression of Sprouty4 compared to MCF10.CA1d/S1
cells, allowing for the observation of dose-dependent effects.

Stable knockdown of Sprouty4 was achieved in the MCF10.DCIS cell line using
two non-overlapping shRNA constructs. Bacterial stocks containing Sprouty4-targeting
sequences (#RHS3979-9623883; #RHS3979-9623885) or an empty vector control
(#RHS4080) were obtained from GE Dharmacon (Lafayette, CO). Plasmids were
extracted and purified using Biorad‘s Quantum Prep Plasmid Miniprep Kit (Hercules,
CA), and their sequences were verified using Sanger sequencing services provided by
Genewiz (South Plainfield, NJ). The antisense construct sequences were as follows:
ATAGTTGACCAGAGTCTGGGC
ATGTGGTCTAAGAGCCGTTGG

for
for

knockdown
knockdown

#2

#1

(#RHS3979-9623883),

(#RHS3979-9623885),

and

ACCGGACACTCGAGCACTTTTTGAATTC for the empty vector control (#RHS4080).
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Neither of the knockdown constructs were found to target SPRY1 or SPRY2 using the
NCBI Blastn alignment search as well as through manual sequence reading. HEK293T
cells were used to package 3.5 µg of construct inside lentivirus as previously described
(Li, Mullins et al. 2008). MCF10.DCIS cells were transduced for six hours then allowed
to recover for two days before starting negative selection with 5 µg/mL puromycin.
Cultures were maintained in growth medium containing 2.5 µg/mL puromycin.
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2.4 siRNA-mediated Transient Knockdown of Sprouty4 in MCF10.DCIS cells
1x105 cells were seeded in each well of a 6-well plate and allowed to grow for
three subsequent days. On day one, cells were transfected with a complex composed of
lipofectamine 2000 and 30 nM siRNA (final concentration) obtained from GE
Dharmacon (Lafayette, CO). The siRNA target sequences were as follows:
GCACGAAUGAGGACGAUGA

for

SPRY4

siRNA

#1

(#D-015457-01-0002),

UGUGGAGAAUGACUACAUA

for

SPRY4

siRNA

#2

(#D-015457-02-0002),

CAACGGCUCUUAGACCACA for SPRY4 siRNA #3 (#D-015457-03-0002), and
UAGCGACUAAACACAUCAA for the non-targeting control siRNA (#D-001210-01-05).
None of the constructs were found to target SPRY1 or SPRY2 using the NCBI Blastn
alignment search as well as through manual sequence reading. Briefly, siRNA and
lipofectamine 2000 were each diluted in opti-MEM reduced serum medium, then mixed
and allowed to form complexes for 20 minutes. After these complexes were created,
500 µL was mixed with growth medium 1:1 and added to each well. siRNA was allowed
to incubate with the cells for four hours before an additional 1mL of growth media was
added to each well. Cells were incubated this way for the next 48 hours and then
harvested.
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2.5 Immunohistochemical Staining and Analysis of Patient Tissue Samples
Tissue microarrays (TMA) BR8011 (enriched for normal and DCIS tissues),
BR487b (enriched for triple-negative or TN IDCs) and BR1504a (enriched for human
epidermal growth factor receptor-2 or HER2, and estrogen/progesterone receptor or
ER/PR expressing IDCs) were purchased from Biomax (Rockville, MD). Slides were
processed for immunohistochemistry (IHC) using optimized protocols and antibodies for
Sprouty4 (ab115557) and phosphorylated ERK1/2 (D13.14.4E; #4370). Indica Labs‘
TMA software module (Corrales, NM) was used to segment the tissue spots on the slide
and measure Sprouty4 and phosphorylated ERK1/2 staining. Paraffin sections were dewaxed in a xylene-ethanol series. Endogenous peroxides were removed by 1.2%
hydrogen peroxide/methanol incubation at room temperature for 30 minutes. Heatinduced epitope retrieval was performed with a pH 6 citrate buffer in a BIOCARE
Decloaking Chamber. A one-hour blocking step with 10% goat serum in PBS was done
prior to adding primary antibody overnight. Detection was performed using Life
Technologies Broad Spectrum 3,3'-diaminobenzidine SuperPicTure Polymer Detection
Kit (#879663), and counterstained with Mayer‘s Hematoxylin. Sections were then
dehydrated through a series of ethanol to xylene washes and cover slipped with
Permount (Thermo Fisher Scientific). The staining for phosphorylated ERK1/2
(pERK1/2) was then classified as percent negative, weak, moderate or strongly positive,
taking the entire analysis region into consideration. Percent positive stain of Sprouty4
was also analyzed. Images of representative tissue spots were taken at 20x
magnification using a Zeiss Axiovert 200 light microscope.
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2.6 2D Immunocytochemistry
Immunocytochemistry was performed as previously described (Mattingly 2003)
with the following exceptions: Blocking was performed with 3% BSA/PBS for two hours
at room temperature, followed by incubation with primary anti-E-cadherin antibody
(1:500) overnight at 4°C. The next day, Alexa Fluor 555 donkey anti-mouse fluorescent
secondary antibody and fluorescein isothiocyanate labeled phalloidin were each diluted
1:500 in 3% BSA/PBS and applied for two hours at room temperature. DAPI was
subsequently diluted 1:1000 in PBS and applied to the chambers for 10 minutes.
Following this, the samples were washed 5x for five minutes each with PBS and then
aspirated dry from one corner. Coverslips were mounted using vectamount antifade
solution and cells were imaged on a LSM 780 confocal microscope (Carl Zeiss
Microscopy, Thornwood, NY, USA) using a 63x objective.
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2.7 3D Immunocytochemistry
100 µL of 16 mg/mL Cultrex was administered to the center of each 35 mm dish
and incubated at 37°C for 30 minutes to accelerate solidification of the matrix.
Simultaneously, a single-cell suspension in assay medium containing 8000 cells/mL
was generated. 400 cells were then seeded on top of the matrix and allowed to attach
for 45 minutes. Two milliliters of assay medium were then added to each dish and
cultured for eight days. Once ready, each dish was aspirated and subjected to the
following: rinsed once with warm PBS; fixed with cold 4% paraformaldehyde for 20
minutes; rinsed again with warm PBS; permeabilized with cold 0.2% Triton X-100/PBS
for 10 minutes; quenched 3x for five minutes with 0.75% Glycine/PBS; rinsed twice with
warm PBS; blocked with 3% BSA/PBS for one hour at room temperature; incubated
with primary anti-E-cadherin antibody (1:500) overnight at 4°C. The next day each
culture was washed 3x for 10 minutes with warm PBS, then Alexa Fluor 555 donkey
anti-mouse fluorescent secondary antibody and fluorescein isothiocyanate labeled
phalloidin were each diluted 1:500 in 3% BSA/PBS along with DAPI (1:1000) and
applied for two hours at room temperature. Finally, three 10 minute washes with warm
PBS were performed. Images were collected with a Zeiss LSM 510 Meta nonlinear
optical confocal microscope (Carl Zeiss Microscopy, Thornwood, NY, USA) using a 63x
water immersion objective. 3D reconstructions of optical sections were generated using
Volocity software v.6.3.1 as described previously (Jedeszko, Sameni et al. 2008).
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2.8 Live Cell Proteolysis Assay
Live cell proteolysis was studied as previously described (Jedeszko, Sameni et
al. 2008) with the following exceptions: 100 μL of Cultrex containing 25 μg/mL dyequenched (DQ)-collagen IV were incubated for 30 min at 37°C to accelerate
solidification of the matrix. During this time a single-cell suspension containing 5000
cells/mL of assay medium was generated, and 250 cells were seeded on top of the
matrix (once retrieved) and allowed to attach for 45 minutes. Two milliliters of assay
medium were then added to each dish and cultured for eight days. Drugs were
administered 48 hours before imaging on a LSM 780 confocal microscope (Carl Zeiss
Microscopy, Thornwood, NY, USA) equipped with a 40x water immersion objective and
controlled environmental chamber that maintains a 5% CO 2/humidified atmosphere at
37°C. Cell nuclei were stained using Hoechst 33342 and proteolysis was gauged by
generation of green fluorescent degradation products. 3D reconstructions of optical
sections were generated and the amount of proteolytic degradation per cell was
quantified using Volocity software v.6.3.1 as described previously (Jedeszko, Sameni et
al. 2008). En face images of 3D reconstructed optical sections were taken to show
fluorescent cleavage products. Data were collected from three independent experiments
performed in triplicate.
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2.9 Immunoblotting
2D cultures: Immunoblotting was performed as previously described (Mattingly
2003) with the following exceptions: SDS-PAGE using minigels was executed for ~90
minutes at constant voltage (100V) before minigels were transferred overnight at 30V.
After blocking solution was removed and the membrane rinsed with TBS-T, primary
antibody was incubated overnight at 4°C. The following day after removal of the primary
antibody and washing steps were complete, secondary antibody was incubated with the
membrane for one hour then washed 2x for 10 minutes with TBS-T.
3D cultures: 5x105 cells were seeded and grown for eight days in culture. Media
were aspirated and cultures were stored on ice. Each dish was briefly rinsed with PBS,
then lysates were collected in the presence of a PBS-EDTA/inhibitor solution (PBSEDTA 5 mM, pH 7.4; 50 mM Na₃VO₄; 500 mM NaF; 25 µg/mL leupeptin; 25 µg/mL
aprotinin; 174 µg/mL phenylmethylsulfonyl fluoride). Lysates were centrifuged at 4°C
and 900g for three minutes then the remaining solution was aspirated. RIPA buffer
supplemented with the same inhibitors as described above was then added. Lysates
were resuspended, subjected to brief sonication, then mixed with 2x Laemmli buffer
[described here (Mattingly 2003)] and heated at 100°C for 5 minutes. Because protein
concentrations could not be used to standardize the lysates (due to the presence of the
matrix), the lysates were initially loaded based on volume and tested for content of
tubulin by immunoblotting. If necessary, loading adjustments were made to equalize the
tubulin contents of the samples. SDS-PAGE and immunoblotting were carried out as
described above for 2D detection.
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2.10 Invasion Assays
6x105 pLKO.1 MCF10.DCIS control or pLKO.1 MCF10.DCIS Sprouty4
knockdown cells were seeded in serum-free media on BD cell culture inserts (8 µm pore
size; Franklin Lakes, NJ) pre-coated with 1.5 mg/mL Cultrex. Inserts were placed in a
24-well plate and cells were allowed to invade toward serum-containing growth media
for 24 hours. After this period, cells that did not invade were removed using cotton
tipped applicators and each filter (containing the invasive cells) was stained using the
Kwik-Diff stain kit (Thermo Fisher Scientific) per the manufacturer‘s instructions. Filters
were mounted and subsequently visualized using a Zeiss Axiovert 200 light microscope
(Carl Zeiss Microscopy, Thornwood, NY, USA). Invading cells were counted by ImageJ
software (NIH) with the help of two blinded individuals. Data were collected from three
independent experiments performed in triplicate.
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CHAPTER 3: RESULTS

3.1 Sprouty4 Expression and ERK1/2 Phosphorylation Are Inversely Related in
Human Patient Tissues
Our previous work has examined networks and pathways relevant to in situ
breast disease (Kaur, Mao et al. 2012). To do this we used transcriptomic analyses to
compare the expression profiles of three DCIS cell lines to a non-transformed breast
epithelial cell line. Cells were grown in 3D rBM overlay cultures because research has
shown that the behavior of cancer cells in 3D matrices is more reflective of an in vivo
response when exposed to drugs and radiotherapy than if they are cultured on plastic
(Hebner, Weaver et al. 2008, Horning, Sahoo et al. 2008, Martin, Patrick et al. 2008, Li,
Chow et al. 2010, Nam, Onodera et al. 2010). Bioinformatics performed on these data
identified promising candidate genes. We recently showed that the reduced expression
of one such candidate, RAP1GAP, is a potential switch for progression toward an
invasive phenotype (Shah, Brock et al. 2018). An equally strong candidate from this
screen was SPRY4, which encodes the protein Sprouty4. Analysis of IDC vs. normal
breast tissue using the Oncomine database showed that SPRY4 transcript was
significantly underexpressed in IDC samples in both the TCGA (p = 1.06x10-5) and
Curtis Breast (p = 8.78x10-10) datasets (see Figures 3.1 and 3.2, respectively).
Additionally,

data

from

The

Human

Protein

Atlas

(https://www.proteinatlas.org/ENSG00000187678-SPRY4/tissue) comparing normal and
cancerous tissue expression revealed Sprouty4 to be lower in the majority of breast

51

cancer samples when compared to normal tissue (7 of 12). Taken together, these data
support the importance of Sprouty4 in DCIS and prompted further investigation.
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Figure 3.1 SPRY4 transcript decreases for IDCs compared to normal tissue in the TCGA Breast
dataset. Data mining of the TCGA Breast dataset revealed a 1.53-fold decrease in SPRY4 mRNA
expression in IDCs (n = 389) compared to non-cancerous breast tissue (n = 61). The Student‘s t-test was
−5
employed for statistical analysis; p = 1.05x10 . The Oncomine Platform (Thermo Fisher, Ann Arbor, MI)
was used for analysis and visualization.
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Figure 3.2 SPRY4 transcript decreases for IDCs compared to normal tissue in the Curtis Breast
dataset. Data mining of the Curtis Breast dataset revealed a 1.20-fold decrease in SPRY4 mRNA
expression in IDCs (n = 1556) compared to non-cancerous breast tissue (n = 144). The Student‘s t-test
−10
was employed for statistical analysis; p = 8.78x10 . The Oncomine Platform (Thermo Fisher, Ann Arbor,
MI) was used for analysis and visualization.
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To better evaluate Sprouty4‘s protein expression, human TMAs containing
samples of tumor-adjacent normal breast (n = 24), DCIS (n = 45), and IDC (n = 169)
were stained using IHC. Expression was significantly (p < 0.001) reduced in IDC
samples compared to DCIS or normal tissues (see Figure 3.3 and Figure 3.4A).
Sprouty4‘s reported ability to regulate ERK/MAPK signaling prompted staining for
phosphorylated ERK1/2. Relatively large amounts of weak ERK1/2 phosphorylation
were detected in normal and DCIS tissues whereas moderate and strong ERK/MAPK
phosphorylation was significantly (p < 0.001) higher in IDC samples (see Figure 3.3 and
3.4B). This inverse relationship between Sprouty4 expression and phosphorylated
ERK1/2 signaling was present both when IDC sample data were pooled (see Figures
3.4A/B) as well as when they were separated into ER/PR+ (n = 67), HER2+ (n = 22),
and TN (n = 80) breast cancer subtypes (see Figures 3.4C/D).
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Figure 3.3 Staining for Sprouty4 is reduced and for ERK1/2 phosphorylation is increased in human
IDCs relative to normal and DCIS tissue. Tissue microarrays containing samples of human normal
tumor adjacent breast, n = 24; DCIS, n = 45; and IDC, n = 169; were processed for IHC using optimized
protocols and antibodies for Sprouty4 and phosphorylated ERK1/2 (pERK1/2). Sprouty4 and pERK1/2
expression levels depicted for each tissue represent median staining values type; size bar = 100 μm.
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Figure 3.4 Sprouty4 levels are significantly reduced in human IDCs relative to normal and DCIS
tissues whereas phosphorylated ERK1/2 shows the opposite pattern. Human tissue microarrays
(TMAs) containing samples of normal breast tissue adjacent to tumor, n = 24; DCIS, n = 45; and IDC, n
= 169; were processed for IHC using optimized protocols and antibodies for Sprouty4 and
phosphorylated ERK1/2 (pERK1/2). One-way ANOVA employing Tukey‘s multiple comparison test
showed significant differences in cytosolic Sprouty4 expression when comparing normal or DCIS tissue
to IDC that was pooled or separated by subtype (α = 0.001, 99.9% CI; *** p < 0.001). Whiskers
represent the minimum and maximum values and bars represent the median. (B, D) A Kruskal-Wallis
test employing Dunn‘s test of multiple comparisons showed significant differences in pERK1/2
expression when comparing normal or DCIS tissue to IDC that was pooled or separated by subtype (α =
0.001, 99.9% CI; *** p < 0.001).
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3.2 Sprouty4 Is Highly Expressed at the DCIS Stage and Lost with Transition to
IDC in the MCF10 Progression Series
To further define the role of Sprouty4 in DCIS and IDC we interrogated protein
levels using the MCF10 series as a model of breast cancer progression. This series of
isogenic cell lines recapitulates the various stages of progression, from non-transformed
epithelium to malignant basal-like disease (Miller, Soule et al. 1993, Dawson, Wolman
et al. 1996, Heppner and Wolman 1999, Miller 2000, Miller, Santner et al. 2000,
Santner, Dawson et al. 2001, Maguire, Peck et al. 2016). The MCF10 series includes
non-transformed breast epithelial cells (MCF10A), premalignant variants (MCF10AT
and MCF10DCIS), as well as malignant variants (MCF10CA) (Miller, Soule et al. 1993,
Heppner and Wolman 1999, Miller, Santner et al. 2000, Santner, Dawson et al. 2001,
Brock, Ji et al. 2019). We tested whether this in vitro system recapitulated the pattern of
Sprouty4 expression that we observed in the IHC results from patient tissue.
Immunoblotting of 3D culture lysates showed high Sprouty4 expression in the
premalignant MCF10.DCIS cell line, as well as a decrease in the invasive MCF10.CA1d
cell line (see Figure 3.5). In contrast, Sprouty1 levels remained constant across the
series. While Sprouty2 expression also decreased in MCF10.CA1d cells relative to
MCF10.DCIS, no increase in protein expression was observed between the
MCF10.AT1 and MCF10.DCIS lines. These data suggest that Sprouty4 is the most
relevant family member under pre-invasive DCIS conditions.
Decreased levels of Sprouty4 expression in the invasive MCF10.CA1d model
prompted the creation of two independent retroviral overexpressions of Sprouty4
(MCF10.CA1d/S1 and MCF10.CA1d/S2) in order to determine the importance of its
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loss. Of these, the MCF10.CA1d/S2 cells exhibited a stronger overexpression. Slug is a
transcription factor downstream of the ERK/MAPK cascade (Joannes, Grelet et al.
2014, Ding, Fang et al. 2015). In breast cancer cells prolonged pharmacological
inhibition (i.e., 48 hours) of the ERK/MAPK pathway decreases protein expression of
Slug and inhibits migration (Chen, Zhu et al. 2009). These data suggest that Slug can
be used as a surrogate marker for chronic ERK1/2 activity in 3D culture. In line with our
IHC data,

cell lines

with

stronger Sprouty4

expression

(i.e.,

MCF10.DCIS,

MCF10.CA1d/S1 and MCF10.CA1d/S2) exhibited lower levels of Slug, suggesting that
active ERK1/2 signaling was also lower (see Figure 3.5). This aligns with our IHC data,
where Sprouty4 expression was inversely related to ERK1/2 phosphorylation.
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Figure 3.5 Sprouty4 is highly expressed at the DCIS stage of the MCF10 progression series. The
progression series represents triple-negative models of: atypical hyperplasia (MCF10.AT1), ductal
carcinoma in situ (MCF10.DCIS), and invasive ductal carcinoma (MCF10.CA1d). MCF10.CA1d/S1 (S1)
and MCF10.CA1d/S2 (S2) represent two independent retroviral overexpressions of Sprouty4 in
MCF10.CA1d cells where the transduced Sprouty4 construct migrates at a molecular weight of 37 kDa
compared to 35 kDa for endogenous Sprouty4. Cultures were grown in 3D reconstituted basement
membrane overlay conditions for eight days. Membranes were immunoblotted for Sprouty4, Sprouty1,
Sprouty2, Slug, and β-tubulin. Expression levels are representative of three independent experiments.
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3.3 Modulation of Sprouty4 Expression Regulates ERK1/2 Phosphorylation in
Cellular Models of IDC
In order to directly characterize whether or not increasing Sprouty4 led to a
decrease in ERK1/2 signaling, we performed an acute stimulation experiment.
MCF10.CA1d as well as MCF10.CA1d/S1 and MCF10.CA1d/S2 cells grown in 2D were
serum starved for 24 hours, then treated with DMSO or 200 nM phorbol 12-myristate
13-acetate for 10 minutes.

Both

the MCF10.CA1d/S1 and MCF10.CA1d/S2

overexpression lines (here S1 and S2) exhibited significantly lower levels of
phosphorylated ERK/MAPK under both stimulated (p < 0.001) and unstimulated (p <
0.01) conditions compared to control (see Figure 3.6).
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Figure 3.6 Overexpression of Sprouty4 in MCF10.CA1d cells suppresses ERK/MAPK
phosphorylation. Top: MCF10.CA1d control and Sprouty4 overexpressing cells (MCF10.CA1d/S1 and
MCF10.CA1d/S2) were grown in 2D culture and treated with either DMSO or 200 nM phorbol 12myristate 13-acetate (PMA) for 10 minutes. Membranes were immunoblotted for Sprouty4,
phosphorylated ERK1/2 (pERK1/2) as well as total ERK1/2, and β-tubulin. Expression levels are
representative of three independent experiments. Bottom: Erk1/2 phosphorylation was quantified using
densitometry and plotted using Graphpad Prism. One-way ANOVA employing a repeated measures test
and Bonferroni correction was used to assess significance (α = 0.01, 99% CI). Whiskers represent the
minimum and maximum values and bars represent the median. Differences were observed under both
unstimulated (** p < 0.01) and stimulated (*** p < 0.001) conditions.
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To better understand how Sprouty4 specifically regulates and responds to
ERK/MAPK signaling, we pharmacologically inhibited MEK1/2 in MCF10.CA1d cells
grown in 2D culture for 48 hours using three different inhibitors (U0126, 10 µM;
PD184352/CI-1040, 100 nM; MEK162/binimetinib, 100 nM) and interrogated the effects
this had on Sprouty4, phosphorylated ERK1/2, phosphorylated MEK1/2, and Slug
compared to control or Sprouty4 overexpressing cells (see Figure 3.7). Treatment with
vehicle or U0124 (a negative control for U0126) showed relatively high ERK1/2
phosphorylation and Slug expression. When MEK inhibitors were administered or
Sprouty4 was overexpressed, ERK1/2 phosphorylation and Slug expression were
reduced. The decrease in ERK1/2 signaling induced by MEK inhibitors was also
accompanied by a reduction in Sprouty4 levels. Importantly, when MCF10.CA1d cells
were treated with PD184352 and MEK162 a feedback loop could be seen, resulting in
increased levels of phosphorylated MEK1/2. With Sprouty4 overexpression the opposite
is true, suggesting that Sprouty4 acts upstream of MEK1/2. This is consistent with
results showing that Sprouty4 acts upstream/at the level of Ras or with Raf proteins
(Leeksma, Van Achterberg et al. 2002, Sasaki, Taketomi et al. 2003, Tsavachidou,
Coleman et al. 2004).
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Figure 3.7 Sprouty4 regulates and responds to the ERK/MAPK pathway. The ERK/MAPK pathway
was targeted in MCF10.CA1d cells cultured in 2D using three separate MEK1/2 inhibitors: U0126 (10
µM), PD184352 (100 nM) and MEK162 (100 nM) for 48 hours. U0124 (10 µM) is a negative control for
U0126. Membranes were immunoblotted for Sprouty4, E-cadherin, Slug, phosphorylated ERK1/2
(pERK1/2), phosphorylated MEK1/2 (pMEK1/2), total ERK1/2, total MEK1/2, and β-tubulin. Expression
levels are representative of three independent experiments.
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3.4 Sprouty4 Overexpression Induces Phenotypic Reversion in MCF10.CA1d
Cells
A modest increase in E-cadherin expression was also observed in MCF10.CA1d
cells treated with MEK inhibitors or overexpressing Sprouty4 (see Figure 3.7). We
hypothesized that this may be a consequence of removing upstream inhibition, as Slug
is thought to be a transcriptional repressor of E-cadherin in breast carcinoma (Hajra,
Chen

et

al.

2002).

To

identify

any

changes

in

E-cadherin

localization,

immunofluorescence for E-cadherin and filamentous actin was performed (see Figure
3.8). MCF10.DCIS, MCF10.CA1d, and MCF0.CA1d cells overexpressing Sprouty4 were
grown in 2D on glass coverslips for four days. During the last 48 hours, MCF10.CA1d
cells were treated with either DMSO vehicle control or 100 nM MEK162. MCF10.DCIS
cells exhibited relatively intact cell-cell junctions with E-cadherin localized to the cell
surface and cortical actin rings (characteristic of epithelial cells). In invasive
MCF10.CA1d cells, a dramatic reorganization of the actin cytoskeleton was visible, and
E-cadherin staining was not localized at the cell surface. However, when Sprouty4 was
overexpressed or the ERK/MAPK pathway was pharmacologically inhibited in
MCF10.CA1d cells, E-cadherin re-localized to the cell surface and there was
reorganization of the actin cytoskeleton (see Figure 3.8).
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Figure 3.8 Sprouty4 overexpression promotes an epithelial-like phenotype. MCF10.DCIS,
MCF10.CA1d control and Sprouty4 overexpressing cell lines (CA1d/S1 and CA1d/S2) were grown in 2D
on glass coverslips for four days. During the last 48 hours CA1d cells were treated with either DMSO or
100 nM MEK162, an allosteric MEK inhibitor. Confocal fluorescent imaging was performed using a 63x
objective. Images show phalloidin-FITC for filamentous actin (green), indirect immunofluorescence for Ecadherin (red), and DAPI for nuclei (blue); size bar = 50 µm. Sprouty4 overexpression and MEK inhibition
lead to the formation of actin cortical ring-like structures, and a change in E-cadherin localization that,
together, resemble an epithelial phenotype. Images are representative of three independent experiments.
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We further investigated the effects of Sprouty4 overexpression and MEK inhibitor
treatment using rBM overlay cultures. 3D structures showed changes in E-cadherin
localization as well as restructuring of the cellular architecture (see Figure 3.9;
Supplementary Videos 1-5) consistent with effects observed in 2D cultures. The partial
formation of acinar-like structures was also observed with Sprouty4 overexpression
(CA1d/S1 and CA1d/S2) as well as MEK inhibition (CA1d MEK162), suggesting these
modifications are able to induce phenotypic reversion (i.e., from invasive structures to
more organized structures). In differential interference contrast images the phenotypic
differences between control MCF10.CA1d cells and experimental MCF10.CA1d cells
that have either been treated with a MEK inhibitor in 2D culture (see Figure 3.10) or
overexpress Sprouty4 in 3D culture (see Figure 3.11) were striking. When levels of
Sprouty4 expression were high, the 3D cellular structures more closely resembled the
spheroids seen with MCF10.DCIS than the parental MCF10.CA1d cell line (see Figure
3.11). Together, these data indicate that changes in E-cadherin expression and
localization, as well as the restructuring of the actin cytoskeleton due to Sprouty4
expression, ultimately occur as a result of regulation of the ERK/MAPK pathway.
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Figure 3.9 Sprouty4 overexpression supports the restoration of E-cadherin. MCF10.DCIS, as well
as MCF10.CA1d control and Sprouty4 overexpressing cell lines (CA1d/S1 and CA1d/S2) were grown in
3D rBM overlay cultures for eight days. During the last 48 hours, CA1d cells were treated with either
DMSO or 100 nM MEK162. Confocal fluorescent imaging was performed using a 63x objective.
Equatorial planes of 3D reconstructions show phalloidin-FITC for filamentous actin (green), indirect
immunofluorescence for E-cadherin (red), and DAPI for nuclei (blue); size bar = 50 μm. The localization of
E-cadherin staining in the Sprouty4 overexpressing and MEK inhibited cells is consistent with relocation
to the cell surface and the restoration of adherens junctions. Images are representative of three
independent experiments.
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Figure 3.10 Pharmacological inhibition of ERK/MAPK signaling leads to changes in cellular
organization. Differential interference contrast images of control and MEK inhibited MCF10.CA1d cells
grown in 2D were captured using a Zeiss Cell Observer spinning disk confocal microscope with a 5x
objective; size bar = 500 µm. The ERK/MAPK pathway was targeted for 48 hours using three separate
MEK1/2 inhibitors: U0126 (10 µM), PD184352/CI-1040 (100 nM), and MEK162/binimetinib (100 nM).
DMSO and U0124 (an inactive form of U0126) served as negative controls. Changes in cellular
organization were observed in each case of MEK inhibition in sharp contrast with control cells. Images
are representative of three independent experiments.
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Figure 3.11 Sprouty4 overexpression induces phenotypic reversion of MCF10.CA1d cells.
MCF10.DCIS, MCF10.CA1d control and Sprouty4 overexpressing cell lines (MCF10.CA1d/S1 and
MCF10.CA1d/S2) were grown in 3D rBM overlay cultures. By 48 hours, structural differences were
observed between the MCF10.CA1d and overexpression lines. Sprouty4 overexpressing cells exhibited
phenotypic reversion and resembled the isogenic DCIS line more than the parental invasive line.
Differential interference contrast images were captured on a Zeiss Cell Observer spinning disk confocal
microscope using a 5x objective and stitching nine fields (3x3) together to ensure reproducibility; size bar
= 500 μm. Images are representative of three independent experiments.
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3.5 Overexpression of Sprouty4 Negatively Regulates Cellular Proteolysis while
Knockdown Increases ERK Signaling and Promotes Invasion
In addition to governing proliferation and survival, the ERK/MAPK pathway is
known to promote invasion (McCawley, Li et al. 1999, Wyganowska-Swiatkowska,
Tarnowski et al. 2019). Interestingly, preventing ERK activation in cancer cells has led
to decreased gene expression and enzymatic activity of MMP-9 (Gum, Wang et al.
1997, McCawley, Li et al. 1999). This proteinase has also been linked to extracellular
proteolysis and was shown to be modulated by Sprouty4 expression in lung cancer
(Tennis, Van Scoyk et al. 2010). These findings, our data, as well as the importance of
the ERK/MAPK pathway in breast cancer led us to ask if Sprouty4 expression was
sufficient to alter the invasive phenotype of breast cancer cells in vitro. To answer this,
we performed live cell proteolysis assays which assess the invasive characteristics of
these multi-cellular structures via their ability to cleave quenched fluorescent proteins
mixed into the surrounding stroma, in this case degradation of DQ-collagen IV mixed
into

rBM

(Jedeszko,

Sameni

et

al.

2008).

MCF10.DCIS,

MCF10.CA1d/S1,

MCF10.CA1d/S2, and MCF10.CA1d cells treated for 48 hours with either DMSO vehicle
control or 100 nM MEK162 were grown in 3D culture for eight days and DQ-collagen IV
cleavage products were quantified on a per cell basis (see Figure 3.12). Significant
decreases in DQ-collagen IV proteolysis were observed with Sprouty4 overexpression
(p < 0.001) as well as MEK inhibition (p < 0.05). Because this change in proteolysis
appeared to correspond to the level of ERK/MAPK phosphorylation (see Figure 3.7),
transient knockdowns of Sprouty4 using three non-overlapping siRNA constructs were
performed. As shown in Figure 3.13, knockdown of Sprouty4 in MCF10.DCIS cells
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resulted in increased ERK1/2 phosphorylation. These observations further prompted the
generation of two independent, stable shRNA knockdowns of Sprouty4 in MCF10.DCIS
(see Figure 3.14A). In Boyden chamber invasion assays, these stable knockdown lines,
as well as MCF10.CA1d cells which acted as a positive control, showed significant
increases (p < 0.01 and p < 0.001, respectively) in invasion compared to DCIS control
(see Figures 3.14B/C). Taken together, these data strongly implicate Sprouty4 as a
regulator of DCIS cell invasion.
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Figure 3.12 MCF10.CA1d cells exhibit an aggressive phenotype that can be reduced by MEK
inhibition and overexpression of Sprouty4. MCF10.DCIS, MCF10.CA1d control and Sprouty4
overexpressing cells were grown in 3D rBM overlay cultures containing dye-quenched collagen IV for
eight days, then imaged live. During the last 48 hours, CA1d cells were treated with either DMSO or 100
nM MEK162. Collagen-IV degradation products (green) are shown in en face views of 3D reconstructions
of optical sections; 1 grid unit = 21 μm. The volume of degradation products was quantified per cell using
Volocity and plotted using Graphpad Prism. One-way ANOVA employing Bonferroni‘s correction was
used to assess significance (α = 0.05, 95% CI). Whiskers represent the minimum and maximum values
and bars represent the median. Statistically significant decreases in proteolytic activity were observed
upon MEK inhibition and Sprouty4 overexpression (* p < 0.05; *** p < 0.001).
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Figure 3.13 Transient knockdown of Sprouty4 in MCF10.DCIS cells enhances ERK/MAPK
signaling. MCF10.DCIS cells were grown in 2D culture, then transfected with either a non-targeting
control siRNA or one of three non-overlapping siRNA constructs targeting SPRY4 for 48 hours.
Membranes were immunoblotted for phosphorylated ERK1/2 (pERK1/2), total ERK1/2, Sprouty4,
Sprouty1, Sprouty2, and β-tubulin. Expression levels are representative of three independent
experiments.
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Figure 3.14 Stable knockdown of Sprouty4 in MCF10.DCIS cells promotes invasion. (A)
MCF10.DCIS cells were infected with lentivirus containing either vector control or Sprouty4-targeting
shRNA constructs. Membranes were immunoblotted for Sprouty4, Sprouty1, Sprouty2, and β-tubulin. (B)
pLKO.1 DCIS control, pLKO.1 DCIS Sprouty4 knockdown, and MCF10.CA1d cells were then serumstarved overnight, and allowed to invade though 1.5 mg/mL of matrix for 24 hours via Boyden chamber
assay. Representative images of cellular invasion (scale bar = 500 µm). (C) Invasion was quantified and
plotted using GraphPad Prism. A Kruskal-Wallis test employing Dunn‘s test of multiple comparisons
showed significant differences in invasion when comparing Sprouty4 knockdown or MCF10.CA1d cell
lines to control (α = 0.01, 99% CI; ** p < 0.01, *** p < 0.001). Whiskers represent the minimum and
maximum values and bars represent the median.
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CHAPTER 4: DISCUSSION

Sprouty was initially characterized as an antagonist of FGF signaling during
Drosophila development (Hacohen, Kramer et al. 1998). Since then, a sizable body of
literature has established that this regulatory protein and its mammalian homologs
(Sproutys1-4) primarily act to suppress growth factor-induced ERK signaling (MasoumiMoghaddam, Amini et al. 2014). In breast cancer, the overactivation of ERK/MAPK
signaling is well documented (Santen, Song et al. 2002, McCubrey, Steelman et al.
2007). Our staining of normal, DCIS, and IDC breast tissues corroborates this
observation in that significantly more ERK/MAPK phosphorylation is present in IDC
tissues compared to normal breast samples. Importantly, we observed a similar pattern
when comparing the levels of ERK/MAPK phosphorylation between invasive and DCIS
tissues. This is likely the result of growth suppressors or other regulatory measures
actively working to keep these premalignant lesions in check. The nature of this
regulation is still somewhat unclear. Therefore, identifying molecular alterations that
consistently differ between in situ and invasive disease remains a priority (Polyak 2010,
Sgroi 2010, Brock, Ji et al. 2019, Hanna, Parra-Herran et al. 2019).
Loss of Sprouty4 has been previously reported for a number of different cancers.
In prostate, colorectal, and hepatocellular carcinomas the SPRY4 transcript has been
shown to be lower in comparison to the respective normal tissues (Wang, Thompson et
al. 2006, Sirivatanauksorn, Sirivatanauksorn et al. 2012, Zhou, Xie et al. 2016).
Decreased expression has also been noted at the protein level in endometrial
adenocarcinoma (Zhang, Guo et al. 2016). To the best of our knowledge, the present
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study is the first to suggest a role for Sprouty4 in limiting premalignant breast lesions
from transitioning to invasive disease. Analysis of IDC vs. normal breast tissue using the
Oncomine database showed that the SPRY4 transcript is significantly underexpressed
in IDC samples in both the TCGA (p = 1.06x10-5) and Curtis Breast (p = 8.78x10-10)
datasets. These data differ from a previously published meta-analysis conducted by
Faratian et al. in which no significant differences in the SPRY4 transcript were found
between invasive and normal breast tissues (Faratian, Sims et al. 2011). One possible
explanation for this difference is the quantity of tumor samples interrogated (42 vs. 389
or

1556).

In

addition,

we

validated

our

findings

in

patient

tissues

by

immunohistochemistry, demonstrating that Sprouty4 expression is significantly lower in
invasive samples relative to DCIS and normal breast. This pattern prevails when IDCs
are pooled as well as when they are separated into hormone positive, HER2 amplified
or triple-negative categories, indicating that loss of Sprouty4 is not an event specifically
tied to a single clinical subtype of breast cancer. We were able to reproduce this loss of
Sprouty4 expression between DCIS and IDC using 3D culture techniques and the
MCF10 series to model breast cancer progression. Knockdown of Sprouty4 in
MCF10.DCIS

cells

substantially

increased

ERK/MAPK

signaling

whereas

overexpression in invasive MCF10.CA1d cells decreased ERK/MAPK signaling.
The RTK/Ras/ERK pathway continues to garner a high level of scientific interest
(Pearson, Robinson et al. 2001, Ashton-Beaucage and Therrien 2017, Wang and Mao
2019). This is likely because it plays a critical role in a number of cellular functions (e.g.,
proliferation, differentiation, invasion) where the activity of key pathway members are
tightly regulated spatially and temporally (Brown and Sacks 2009). One way that this
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regulation is frequently circumvented in cancer is through gain-of-function mutations in
three of the central players: RTKs (e.g., EGFR), Ras, and Raf (Dhillon, Hagan et al.
2007).
While present as mutated, driving oncogenes in certain tumors there is also
significant evidence that wild-type Ras isoforms contribute to the malignant phenotype
(Mattingly 2013). For example, in breast carcinoma there is a common theme of Ras
pathway activation through multiple mechanisms, including neurofibromin loss and
overexpressed growth factor receptors, while Ras mutations themselves are rarely
found (Eckert, Repasky et al. 2004, Wallace, Pfefferle et al. 2012). Due to difficulties in
directly targeting Ras or its association with membranes [reviewed in (Brock, Ji et al.
2016)], most efforts have shifted to developing targeted inhibitors of downstream
proteins driven by activated Ras (Baines, Xu et al. 2011, Cox, Fesik et al. 2014). This
strategy has been vindicated by the FDA‘s approval of three MEK1/2 inhibitors:
trametinib in 2013, cobimetinib in 2015, and MEK162/binimetinib in 2018

(in

combination with the Raf inhibitors dabrafenib, vemurafenib, and encorafenib,
respectively) for the treatment of advanced melanoma with a BRAF V600E or V600K
mutation (Wright and McCormack 2013, Ascierto, McArthur et al. 2016, Dummer,
Ascierto et al. 2018, Dummer, Ascierto et al. 2018). In our study, pharmacological
inhibition of MEK1/2 in MCF10.CA1d cells reduced ERK/MAPK signaling as expected,
and also reduced Sprouty4 expression. This indicates that with less active ERK1/2
signaling to regulate there is a decreased need for Sprouty4 expression. Collectively,
these data, the previously mentioned Sprouty4 knockdown and overexpression
experiments, as well as the tissue staining for ERK1/2 phosphorylation demonstrate
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Sprouty4‘s ability to regulate and respond to ERK/MAPK signaling in premalignant
breast tissue and suggest that loss of its regulation in IDC may be important for the
transition to invasive disease.
Although this work does not directly address binding or where in the pathway
Sprouty4 acts, two potentially useful pieces of information can be gleaned from our
studies. The first is that Sprouty4 operates upstream of MEK1/2. This can be inferred
from the reduction of phosphorylated MEK when Sprouty4 is overexpressed in
MCF10.CA1d cells as it contrasts with the substantial increase seen when
MCF10.CA1d cells are treated with nanomolar concentrations of the MEK inhibitors
PD184352 or MEK162. Pharmacological inhibition of MEK leads to the depletion of
ERK1/2 signaling and prevents the feedback signaling normally responsible for MEK
dephosphorylation. As this pattern is not present with Sprouty4 overexpression, one
may reasonably assume that this protein performs its regulatory function further
upstream in the pathway. These data are consistent with literature showing that
Sprouty4 acts at the level of Ras or with Raf proteins (Leeksma, Van Achterberg et al.
2002, Sasaki, Taketomi et al. 2003, Tsavachidou, Coleman et al. 2004).
The second, more intriguing piece of the puzzle is tangential to prior work from
our laboratory showing increased levels of activated H-Ras in MCF10.DCIS cells
(inherited from the isogenic MCF10.NeoT cell line which was transformed using a
constitutively active T24-H-Ras) [(Dawson, Wolman et al. 1996, Li and Mattingly 2008)].
This detail is relevant to the present study because knocking down Sprouty4 in
MCF10.DCIS cells dramatically increases ERK/MAPK signaling. Such an increase in
the presence of a constitutively active Ras suggests Sprouty4 may perform its
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regulatory action downstream of Ras, potentially at the level of Raf as previously
reported in melanoma [see Figure 4.1; (Tsavachidou, Coleman et al. 2004)].
Alternatively, Sprouty4 may interact with Ras-GAP as described in Drosophila (Casci,
Vinos et al. 1999). There are caveats to these assumptions, however. The first is that
the role that transduced H-Ras plays in the MCF10 series is unclear, as it has been
reported to be insufficient for producing the premalignant stem cell phenotype (Miller
2000). In addition, all cell lines in the MCF10 series are reliant on growth factor
supplementation suggesting that the proliferation of variants harboring the T24-H-Ras,
such as MCF10.DCIS, is not driven entirely by this oncogene. Further testing of active
Ras and Raf protein levels would be necessary to validate these potential interactions,
ideally using additional DCIS or breast cancer cell lines which do not harbor Ras
mutations. If accurate, this method of regulating ERK/MAPK signaling would add yet
another bullet point to the list of how Sprouty4 behaves differently from Sprouty1 and
Sprouty2 and would underscore Sprouty4‘s biological importance to breast cancer
(Gross, Bassit et al. 2001).
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Figure 4.1 Potential sites for Sprouty4 interaction in RTK-Ras-ERK signaling. Sprouty4 likely exerts
its regulatory function at the level of Ras or Raf.
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To determine whether Sprouty4 expression was sufficient to prevent invasive
progression, live cell proteolysis and Boyden chamber assays were performed.
Overexpression of Sprouty4 or pharmacological inhibition of MEK1/2 in MCF10.CA1d
cells significantly decreased the level of proteolysis. As degradation of the extracellular
matrix is an important part of tumor growth and invasion, these data imply that Sprouty4
overexpression and MEK inhibition are capable of reducing the aggressiveness of
MCF10.CA1d cells. Boyden chamber assays showed significant increases in invasive
capacity for MCF10.DCIS cells exhibiting reduced Sprouty4 expression. Together, these
data indicate that Sprouty4 loss contributes to disease progression. Ultimately, this
change in invasive capability appears to be linked to suppression of ERK1/2
phosphorylation by Sprouty4 since inhibiting MEK1/2 in MCF10.CA1d cells decreases
degradation of the basement membrane protein type IV collagen, and reduction of
Sprouty4 expression in MCF10.DCIS cells increases levels of phosphorylated ERK1/2.
These data are consistent with a role for the ERK pathway in promoting cell invasion
(Tanimura and Takeda 2017).
Overexpressing Sprouty4 in invasive MCF10.CA1d cells, in addition to
suppressing ERK1/2 phosphorylation, leads to changes in Slug, E-cadherin, and the
actin cytoskeleton. A reduction in levels of Slug is likely explained by its role as a
transcription factor downstream of the ERK/MAPK cascade (Joannes, Grelet et al.
2014, Ding, Fang et al. 2015). Prolonged inhibition (i.e., 48 hours) of the ERK/MAPK
pathway in breast cancer cells has been shown to decrease Slug expression and inhibit
cell migration (Chen, Zhu et al. 2009). We also observe modest increases in E-cadherin
protein expression upon Sprouty4 overexpression or MEK inhibition, and suspect this is
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related to the reduction in Slug levels due to Slug‘s purported transcriptional repression
of E-cadherin in breast carcinoma (Hajra, Chen et al. 2002). Our previous work showing
that MAPK inhibition was able to completely restore E-cadherin cell-cell junctions
prompted inspection of E-cadherin localization (Li and Mattingly 2008). We
demonstrated that in MCF10.CA1d cells overexpressing Sprouty4 or treated with a MEK
inhibitor E-cadherin localizes to the cell surface and the actin cytoskeleton is
dramatically reorganized to resemble an epithelial morphology. This contrasts with prior
work by Tsumura et al. in which Sprouty4 was reported to regulate the actin
cytoskeleton independently of the ERK/MAPK pathway (Tsumura, Toshima et al. 2005).
Possible explanations for this difference include differences in cell lines used as well as
the duration (20 minutes vs. 48 hours) and concentration (20 µM vs. 100 nM) at which
MEK inhibitors were applied.
As previously mentioned, identifying molecules whose expression consistently
differs between in situ and invasive disease remains an important research goal.
Attempts to address this objective have come in the form of gene expression panels like
the Oncotype DX DCIS Score, transciptomic analyses such as the one performed by
our laboratory, as well as the proposition of candidate biomarkers. Prognostic
biomarkers are used to indicate the likely course of disease in an untreated individual
(Oldenhuis, Oosting et al. 2008, Kalia 2015). They mainly benefit lower risk patients
because the information gleaned is then used to select the most appropriate type of
adjuvant treatment (e.g., the addition or absence of radiotherapy after breast
conservation surgery) (Oldenhuis, Oosting et al. 2008). Unfortunately, due to limited
tissue most DCIS biomarker studies are underpowered or diluted by the inclusion of
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samples with an invasive component (Hanna, Parra-Herran et al. 2019). Differences in
IHC scoring methods also have the potential to limit the impact of these studies. While
our IHC staining suggests that Sprouty4 is not a suitable biomarker candidate, our
results collectively support its role in limiting the transition to invasive disease.
In conclusion, we have identified Sprouty4 as an important regulator of
ERK/MAPK signaling in DCIS, thus limiting the progression of these premalignant
breast lesions. Through in silico analyses, IHC staining of human DCIS and IDC patient
tissues, as well as the use of an in vitro 3D model of disease progression we found that
Sprouty4 expression was substantially reduced with progression to IDC. In the absence
of Sprouty4 regulation, ERK/MAPK phosphorylation increased, both in human tissue
and when artificially silenced in cells. Reduction of Sprouty4 also promoted
invasiveness while the opposite was true of overexpression. Images of invasive cells
overexpressing Sprouty4 revealed data consistent with phenotypic reversion, such as
remodeling of the actin cytoskeleton, relocation of E-cadherin back to the cell surface
(suggesting the restoration of adherens junctions), and partial formation of acinar-like
structures. The use of MEK inhibitors confirmed that these effects were ultimately driven
by reductions in ERK/MAPK signaling, as pharmacological inhibition also produced a
phenotype similar to Sprouty4 overexpression.
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Breast ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive
ductal carcinoma (IDC). It is still unclear which DCIS will become invasive and which will
remain indolent. Previous data by our group found that Sprouty4 transcript was
differentially expressed between three DCIS cell lines and a non-transformed breast
epithelial cell line. Sprouty proteins are important regulators of ERK/MAPK signaling,
and have been studied in various cancers. We hypothesized that Sprouty4 is an
endogenous inhibitor of ERK/MAPK signaling and that its loss/reduced expression is a
mechanism by which DCIS lesions progress toward IDC, including triple-negative
disease. Using immunohistochemistry we found that Sprouty4 expression was reduced
in IDC patient samples compared to DCIS, and that ERK/MAPK phosphorylation had an
inverse relationship to Sprouty4 expression. These observations were reproduced using
a 3D culture model of disease progression. Knockdown of Sprouty4 in MCF10.DCIS
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cells increased ERK/MAPK phosphorylation as well as their invasive capability, and
overexpression
phosphorylation

of

Sprouty4

and

the

in

MCF10.CA1d

aggressive

IDC

phenotype

cells

reduced

exhibited

by

ERK/MAPK
these

cells.

Immunofluorescence experiments revealed dynamic changes in the actin cytoskeleton
and data consistent with the relocation of E-cadherin back to the cell surface and the
restoration of adherens junctions. To determine whether these effects were due to
changes in ERK/MAPK signaling, MEK1/2 was pharmacologically inhibited in IDC cells.
Nanomolar concentrations of drug restored an epithelial-like phenotype and reduced
pericellular proteolysis, similar to Sprouty4 overexpression. From these data we
conclude that Sprouty4 acts to control ERK/MAPK signaling in DCIS, thus limiting the
progression of these premalignant breast lesions.
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